

1 Mycotoxin exposure biomonitoring in breastfed and non-exclusively
2 breastfed Nigerian children

3
4 Chibundu N. Ezekiel^{1,2,*}, Wilfred A. Abia^{2,3,4}, Dominik Braun⁵, Bojan Šarkanj^{2,6}, Kolawole
5 I. Ayeni¹, Oluwawapelumi A. Oyedele¹, Emmanuel C. Michael-Chikezie^{7,8}, Victoria C.
6 Ezekiel⁹, Beatrice N. Mark¹⁰, Chinonso P. Ahuchaogu¹¹, Rudolf Krska^{2,3}, Michael
7 Sulyok², Paul C. Turner¹² and Benedikt Warth^{5,*}

8 ¹Department of Microbiology, Babcock University, Ilishan Remo, Ogun State, Nigeria. ²Institute of Bioanalytics and
9 Agro-Metabolomics, Department of Agrobiotechnology (IFA-Tulln), University of Natural Resources and Life
10 Sciences Vienna (BOKU), Konrad Lorenzstr. 20, A-3430 Tulln, Austria. ³Institute for Global Food Security, School of
11 Biological Sciences, Queen's University Belfast, University Road, Belfast, BT7 1NN, Northern Ireland, United
12 Kingdom. ⁴Laboratory of Pharmacology and Toxicology, Department of Biochemistry, Faculty of Science, University
13 of Yaounde I, P.O. Box 812, Yaounde, Cameroon. ⁵University of Vienna, Faculty of Chemistry, Department of Food
14 Chemistry and Toxicology, Währinger Str. 38, A-1090 Vienna, Austria. ⁶Department of Food Technology, University
15 North, Center Koprivnica, Trg dr. Zarka Dolinara 1, HR, 48000, Koprivnica, Croatia. ⁷Clifford University, Owerinta
16 (Ihie Campus), Abia State, Nigeria. ⁸Benjamin Carson (Snr.) School of Medicine, Babcock University, Ilishan Remo,
17 Ogun State, Nigeria. ⁹Independent Researcher, Ilishan Remo, Ogun State, Nigeria. ¹⁰Department of Community
18 Health, Babcock University Teaching Hospital, Ilishan Remo, Ogun State, Nigeria. ¹¹Department of Clinical Sciences,
19 Babcock University Teaching Hospital, Ilishan Remo, Ogun State, Nigeria. ¹²MIAEH, School of Public Health,
20 University of Maryland, College Park, MD 20742, USA.

21 Corresponding authors:

22 *Chibundu N. Ezekiel, Department of Microbiology, Babcock University, Ilishan Remo, Ogun State,
23 Nigeria. Email: chaugez@gmail.com

24 *Benedikt Warth, University of Vienna, Faculty of Chemistry, Department of Food Chemistry and
25 Toxicology, Währinger Straße 38, 1090 Vienna, Austria. Phone: +43 1 4277 70806. E-mail:
26 benedikt.warth@univie.ac.at

27 **Abstract**

28 A multi-specimen, multi-mycotoxin approach involving ultra-sensitive LC-MS/MS analysis of
29 breast milk, complementary food and urine was applied to examine mycotoxin co-exposure in
30 65 infants, aged 1–18 months, in Ogun state, Nigeria. Aflatoxin M₁ was detected in breast milk
31 (4/22 (18%)), while six other classes of mycotoxins were quantified; including dihydrocitrinone
32 (6/22 (27%); range: 14.0–59.7ng/L) and sterigmatocystin (1/22 (5%); 1.2ng/L) detected for the
33 first time. Seven distinct classes of mycotoxins including aflatoxins (9/42 (21%); range: 1.0–
34 16.2µg/kg) and fumonisins (12/42 (29%); range: 7.9–194µg/kg) contaminated complementary
35 food. Mycotoxins covering seven distinct classes with diverse structures and modes of action
36 were detected in 64/65 (99%) of the urine samples, demonstrating ubiquitous exposure. Two
37 aflatoxin metabolites (AFM₁ and AFQ₁) and FB₁ were detected in 6/65 (9%), 44/65 (68%) and
38 17/65 (26%) urine samples, respectively. Mixtures of mycotoxin classes were common,
39 including 22/22 (100%), 14/42 (33%) and 56/65 (86%) samples having 2–6, 2–4, or 2–6
40 mycotoxins present, for breast milk, complementary food and urine, respectively. Aflatoxin
41 and/or fumonisin was detected in 4/22 (18%), 12/42 (29%) and 46/65 (71%) for breast milk,
42 complimentary foods and urine, respectively. Furthermore, the detection frequency, mean
43 concentrations and occurrence of mixtures were typically greater in urine of non-exclusively
44 breastfed compared to exclusively breastfed infants. The study provides novel insights into
45 mycotoxin co-exposures in early-life. Albeit a small sample set, it highlights transition to higher
46 levels of infant mycotoxin exposure as complementary foods are introduced, providing impetus
47 to mitigate during this critical early-life period and encourage breastfeeding.

48 **Key words:** Children; Biomarkers; Breastmilk; Environmental/Public Health; Food Safety;
49 Mycotoxins.

50 **1. Introduction**

51 Nutrition within the first 1000 days of life is crucial to the growth, development and
52 performance of children in their later years and into adulthood as postulated in the
53 'developmental origins of health and disease' (DOHaD) concept (Barker, 2000; Bateson et al.,
54 2004; Mandy and Nyirenda, 2018). However, the sources of children's diets within this period
55 may be diverse, and depend on the age of the children. The dietary patterns in a progressive
56 manner include exclusively consumed breast milk or formula milk, breast milk or formula milk
57 combined with complementary foods, and exclusively consumed complementary foods. Breast
58 milk composition varies widely depending on diet, age, lactation stage, number of pregnancies,
59 and other physiological parameters (Butts et al., 2018; Innis, 2014; Wu et al., 2018). Previous
60 studies have shown that complementary foods can be made from single or mixed cereals as a
61 porridge, sometimes in combination with nuts, animal milk and other mashed items, and
62 additional food groups are added as children get older (Alvito et al., 2010; Chuisseu Njamen et
63 al., 2018; Kamala et al. 2016; Kimanya et al., 2009, 2010, 2014; Ojuri et al., 2018, 2019).
64 Unfortunately, in some parts of the world, some commonly consumed foods contain toxic fungal
65 metabolites known as mycotoxins (Alvito et al., 2010; Braun et al., 2018; Cherkani-Hassani et
66 al., 2016; Juan et al., 2014; Kamala et al., 2016; Kimanya et al., 2009, 2010, 2014; Chuisseu
67 Njamen et al., 2018; Ojuri et al., 2018, 2019; Preindl et al., 2019; Warth et al., 2016).

68 Aflatoxin (AF), fumonisin (FUM), ochratoxin A (OTA), deoxynivalenol (DON) and
69 zearalenone (ZEN) are considered priority mycotoxins and are regulated in food. AFs are
70 categorized as class 1 human liver carcinogen (IARC, 2002, 2012a). AF is additionally
71 implicated in growth faltering of infants, (Gong et al., 2002, 2003, 2004, 2012; Turner et al.,
72 2003, 2007; Watson et al., 2018), possibly associated with interference to micronutrient
73 absorption, impairment of gut integrity, liver homeostasis or effects on the IGF-growth axis

74 (IARC, 2015; Turner, 2013; Watson et al., 2018). FUM intake has been associated with the
75 incidence of esophageal cancer (Chu et al., 1994; Sun et al., 2007, 2011; Yoshizawa et al.,
76 1994), birth defects (Missmer et al., 2006), and suggested to play a role in child growth faltering
77 (Shirima et al., 2015). OTA is linked to renal toxicity (Heussner and Bingle, 2015), while immune
78 system modulation was reported for trichothecenes such as DON (Pestka, 2010). Furthermore,
79 *in vitro* data suggest interactions of regulated mycotoxins with emerging ones such as alternariol
80 (AOH) and its methylated ether form (alternariol monomethyl ether; AME), beauvericin (BEA),
81 enniatins and moniliformin (MON) (Aichinger et al., 2019; Vejdovszky et al., 2017a, 2017b;
82 Woelflingseder, 2019).

83 Complementary foods can be contaminated with mycotoxins (Cappozzo et al., 2017;
84 Chuisseu Djamen et al., 2018; Juan et al., 2014; Kimanya et al., 2009, 2010, 2014; Kolakowski
85 et al., 2016; Ojuri et al., 2018, 2019; Oueslati et al., 2018), and ingested mycotoxins or their
86 metabolites may be found in various bio-fluids including blood, urine and breast milk (Ayelign et
87 al., 2017; Braun et al., 2018; Chen et al., 2017; Cherkani-Hassani et al., 2016; Ediage et al.,
88 2013; Ezekiel et al., 2014; Ferrufino-Guardia et al., 2019; Gerding et al., 2015; Heyndrickx et al.,
89 2015; Papageorgiou et al., 2018; Polychronaki et al., 2008; Sanchez and Diaz, 2019;
90 Schwartzbord et al., 2016; Shirima et al., 2015; Turner et al., 2012a; Warth et al., 2016). Only a
91 limited number of studies have assessed mycotoxin exposure in Nigerian children using
92 biomarkers of exposure (Adejumo et al., 2013; Braun et al., 2018; Ezekiel et al., 2014, 2018b;
93 McMillan et al., 2018; Sarkanj et al., 2018)-.

94 This study aimed at elucidating mycotoxin co-exposure patterns in infants using three
95 measures (food, breast-milk and urine), all with comprehensive quantitative and ultra-sensitive
96 mycotoxin analysis, to compare exposure levels in exclusively breastfed (EB) with non-
97 exclusively breastfed (NEB) infants. Importantly, several classes of mycotoxins were examined,
98 for example aflatoxins, and in bio-fluids (milk or urine) metabolites of such mycotoxins may also

99 be observed in addition or instead of the parent class of toxin, for example aflatoxin M1 or Q1.
100 These metabolites would not be observed in the original food.

101

102 **2. Materials and methods**

103 **2.1 Study area and population**

104 The study population was 65 infants aged 1–18 months from Ilishan and Ikenne in Remo
105 land of Ogun state (south-western Nigeria). Both are small sister communities within 1 km
106 distance of each other, with rich diversity of foods available in households. Both communities
107 are semi-urban due to the presence of campuses of tertiary institutions and they share similar
108 characteristics as detailed below. Indigent families in these communities are farmers and
109 traders, and both communities consist of approximately 15,000 residents (Ezekiel et al., 2018b).
110 The food sources for families are local markets, small stores and own farms. Major foods
111 consumed are cereals (rice, maize, wheat), tubers (cassava and yam), and peanuts, melon
112 seed and cowpea. The dietary patterns for infants in both communities involve exclusive
113 breastfeeding (feeding infants with only breast milk for at least six months from birth) and non-
114 exclusive breastfeeding (the introduction of complementary foods to breastfed infants
115 sometimes from the first month after birth). Dietary pattern depends on family income, mother's
116 health and work status, and knowledge on breastfeeding practices. A majority of the families
117 associated with tertiary institutions in both communities practice exclusive breastfeeding.

118 **2.2 Sampling design and ethical considerations**

119 This pilot, cross-sectional survey was conducted between January and February 2016.
120 Families that participated were identified through local health centres and post-natal clinics in
121 the two communities where mother/infant pairs were registered. The study consisted of two
122 cohorts: exclusively breastfed (EB) children (age: 1–6 months) and non-exclusively breastfed
123 (NEB) children (age: 3–18 months) to which 23 and 42 children (male/female ratio = 31:34)

124 were recruited, respectively. A total of 50 and 15 infants were recruited into the study from
125 Ilishan and Ikenne communities, respectively. The inclusion criteria for this study were age of
126 infants and dietary patterns for each cohort as well as healthy status of infants. The age of
127 infants recruited into the study were ascertained from their health records. Dietary patterns
128 (exclusively breast milk consumption in EB cohort *versus* consumption of breast milk and
129 complementary food in NEB cohort) were ascertained from the mothers. Infants with known
130 medical conditions (e.g., jaundice, HIV positive or visibly malnourished) were excluded during
131 the recruitment stage as it was the purpose of this study to investigate typical background
132 exposure levels and compare EB with NEB rather than targeting the impact of exposure on
133 health status. Prior to recruitment or inclusion into the study, the mother of each child was
134 informed in her preferred language (English or Yoruba) on the purpose of the study. Only
135 mothers who signed the informed consent document (and on behalf of their infant) to participate
136 in the research were included into the study.

137 Complementary foods were obtained as “plate-ready” samples ($n=42$; 50 g each), by a
138 trained team member, for the NEB children ($n=42$) on the day prior to infant urine sample
139 collection. The food samples collected included industrially-processed infant cereal ($n=6$),
140 fermented maize gruel *ogi* ($n=26$) and *tombran* (home-made pudding from mixed cereal and
141 nut; $n=10$). One food sample representing the most frequently consumed food in a day was
142 collected per infant. Breast milk samples ($n=22$; 3–5 mL each), considered as food for the EB
143 infants, were collected from mothers of EB infants on the day preceding the sampling of infant
144 urine. Complementary food and breast milk sample collections on the day prior to infant urine
145 sampling were necessary in order to ensure adequate metabolism and transfer of toxins into
146 urine. One mother did not provide breast milk sample due to intake of medications. Other details
147 of sampling and handling of the breast milk samples were described by Braun et al. (2018). In
148 this paper, the breast milk samples have been previously analysed for mycotoxins utilizing a
149 less sensitive method. In addition, some of the data from the mother-infant pairs with exclusively

150 breastfed infants were used in a recent correlation study by Braun et al. (*in revision*) that added
151 longitudinal aspects and urinary exposure measurements of the mothers.

152 First morning urine samples (10–40 mL each) were collected in 50 falcon tubes from all
153 65 infants recruited into the study by the mothers, using their experience and knowledge of the
154 time at which their infant pass urine in the morning. All samples (plate-ready complementary
155 food, breast milk and urine) were immediately frozen at -20°C and sent by courier on dry ice to
156 Austria for LC-MS/MS analyses.

157 Ethical permission for this study was granted by the Babcock University Health
158 Research Ethics Committee under two approval numbers: BUHREC294/16 for the EB children
159 and BUHREC156/15 for the NEB children. In adherence to ethical standards, all samples were
160 blinded and coded to exclude participant information prior to analytical measurements.

161 **2.3 Demographic, dietary and health status questionnaire**

162 Each mother received a copy of a well-structured questionnaire for completion prior to
163 food, breast milk and urine sample collection. Copies of the questionnaire were administered by
164 trained interviewers and translation to the local language (Yoruba) was available on request of
165 some mothers. The administered questionnaire was designed to elicit information on participant
166 demography, family socio-economic status, individual dietary preferences, food consumption
167 frequencies and quantities, and associated health implications among the infants.

168 **2.4 Mycotoxin determination in breast milk samples**

169 Mycotoxins were quantified in breast milk samples as described in Braun et al. (2020).
170 Briefly, each homogenized breast milk sample (1 mL) was extracted using 1 mL acidified ACN
171 (1% formic acid) on a shaker for 3 min, followed by addition of anhydrous magnesium sulfate
172 (0.4 g) and sodium chloride (0.1 g). Sequel to two rounds of cold centrifugation ($4,750 \times g$ at
173 10°C for 10 min; $14,000 \times g$, 4°C for 2 min), a SPE clean up step using SPE column (Oasis
174 PRiME HLB[®], Waters, Milford, MA, USA) followed. Mycotoxins were then concentrated on a
175 vacuum concentrator (Labconco, Missouri, USA) prior to reconstitution using 81 μL MeOH/ACN

176 and 9 μL of the internal standard mixture. Mycotoxins in breast milk samples were measured on
177 a Sciex QTrap 6500⁺ LC-MS/MS system (Foster City, CA, USA) equipped with a Turbo-V™
178 electrospray ionization (ESI) source coupled to an Agilent 1290 series UHPLC system
179 (Waldbronn, Germany). Analytes were separated on an Acquity HSS T3 column (2.1×100mm;
180 Waters, Vienna, Austria) with 1.8 μm particle size at 40 °C. ESI-MS/MS was performed in
181 scheduled multiple reaction monitoring (MRM) mode using fast polarity switching. For each
182 analyte two individual mass transitions were acquired.

183 The analytical method was in-house validated according to the European Commission
184 Decision 2002/657/EC (EC 2002) and the EuraChem Laboratory Guide (Magnusson, 2014).
185 Limits of detection (LOD) and quantification (LOQ) are reported in Table 2 and the relative
186 standard deviation as obtained during validation was below 9% for all mycotoxins when spiked
187 approximately at their respective LOQ value (Braun et al., 2020). Quality control measures in
188 routine analysis include a pooled non-spiked breast milk sample and three breast milk samples,
189 which are fortified with authentic reference standards at the same concentration levels as during
190 method validation to ensure proper extraction efficiency and instrumental performance.

191 **2.5 LC-MS/MS-based mycotoxin analysis of food samples**

192 Plate-ready complementary food samples were analysed for the presence of multiple
193 mycotoxins according to the dilute and shoot LC-MS/MS-based method described by Sulyok et
194 al. (2020). This method covers the detection of more than 500 metabolites, inclusive of
195 mycotoxins, in food samples. Briefly, 5 g of each food sample was extracted with 20 mL of
196 acetonitrile/water/acetic acid 79:20:1, (v/v/v) in a 50 mL polypropylene tube (Sarstedt,
197 Nümbrecht, Germany) for 90 min on a GFL 3017 rotary shaker (GFL, Burgwedel, Germany).
198 Afterwards, the extract was diluted 1:1 (v/v) in dilution solvent (acetonitrile/water/acetic acid
199 20:79:1, v/v/v) prior to measurement on a Sciex QTrap 5500 LC-MS/MS System (Applied
200 Biosystem, Foster City, CA, USA) equipped with TurbolonSpray electrospray ionisation (ESI)
201 source and a 1290 Series HPLC System (Agilent, Waldbronn, Germany). Chromatographic

202 separation was performed at 25°C on a Gemini® C18-column, 150×4.6 mm i.d., 5 µm particle
203 size, equipped with a C18 4×3 mm i.d. security guard cartridge (Phenomenex, Torrance, CA,
204 USA). ESI-MS/MS was performed in the scheduled MRM mode both in positive and negative
205 polarities in two separate chromatographic runs per sample by scanning two fragmentation
206 reactions per analyte. The MRM detection window of each analyte was set to its expected
207 retention time ± 20 and ± 26 s in the positive and the negative modes, respectively. The
208 identification of each positive analyte was confirmed when two MRMs per analyte was obtained
209 (EC, 2002). Further details on the method performance are described in Sulyok et al. (2020).

210 The analytical method has been fully validated following the SANTE Guide (SANTE,
211 2018) for multi-residue analysis and published (Sulyok et al., 2020). The latter reference is
212 available open access and provides full information on all data on method performance. The
213 ongoing quality control of the method involves participation in a proficiency testing scheme
214 organized by BIPEA. Furthermore, a quality control check sample is included in each analytical
215 sequence. The extended measurement uncertainty has been determined to be 50% (Stadler et
216 al., 2018).

217 **2.6 Urinary mycotoxin measurements by UPLC-MS-MS**

218 Mycotoxins in the urine samples were determined following a stable-isotope dilution
219 assay-based LC-MS/MS method described in detail by Šarkanj et al. (2018). Briefly, each urine
220 sample was centrifuged for 3 min at 5600 x g, then treated β -glucuronidase from *E. coli* Type
221 IX-A (Sigma-Aldrich, G7396-2MU) of prior to a SPE cleanup on Oasis PRiMEHLB® SPE
222 columns (Waters, Milford, MA, USA). Extracts were then evaporated under nitrogen,
223 reconstituted with 470 µL dilution solvent (10% acetonitrile, 0.1% glacial acetic acid) and fortified
224 with 30 µL of an IS mixture. Measurement of mycotoxins in urine samples was performed on a
225 Sciex QTrap 6500+ LC-MS/MS system (Foster City, CA) equipped with a Turbo-V™ ESI source
226 coupled to an Agilent 1290 series UHPLC system (Waldbronn, Germany). Analytes were
227 separated on an AtlantisT3 HSS column (2.1×100mm; Waters, Wexford, Ireland) with 1.8 µm

228 particle size at 35 °C. ESI-MS/MS was performed in scheduled MRM mode and with a 180 sec
229 detection window. At least two individual transitions were monitored for each analyte.

230 The analytical method was in-house validated according to the European Commission
231 Decision 2002/657/EC (EC, 2002). LOD and LOQ values are presented in Table 4. Inter-day
232 relative standard deviation during method validation was calculated to be below 33% for all
233 mycotoxins included in this assay (Šarkanj et al., 2018). During routine analysis, QC samples
234 were assessed on a regularly basis to ensure proper sample preparation and instrumental
235 performance. After each 20 experimental samples a pooled fortified and non-fortified ('blank')
236 urine sample were measured.

237 **2.7 Data analysis**

238 The IBM SPSS Statistics v21.0 (SPSS, Inc., Chicago, IL, USA) was applied in the
239 analyses of all data. A scatter plot was created for the percentage increases in frequencies and
240 means of urinary mycotoxins between the two cohorts of children. For comparison of urinary
241 mycotoxin levels in the population, means were separated by the Duncan's Multiple Range test
242 (DMRT) and tested for significance by analysis of variance (ANOVA) at $\alpha = 0.05$. For the
243 comparison of all other data between the two cohorts of children in the study, the independent
244 sample *t*-test using the Levene's test for equality of variances were applied to test for
245 significance at $\alpha = 0.05$.

246

247 **3. Results**

248 **3.1 Demography and food preference of children**

249 The demographic characteristics of the infants as well as their food consumption data
250 are given in Table 1. The NEB infants were significantly ($p < 0.01$) older (9.0 ± 3.6 months) and
251 heavier (8.0 ± 1.6 Kg; $p < 0.05$) than the EB children (3.7 ± 1.6 months and 6.3 ± 1.0 Kg,

252 respectively). All infants received breast milk at least once daily, with higher consumption
253 frequency of 8–10 times per day in the EB cohort compared to 1–3 times per day in the NEB
254 cohort who received complementary food at least thrice per day. NEB infants received a variety
255 of foods, which in most cases (>90%) included infant cereal (mix of animal milk with maize, rice,
256 or wheat), *ogi* (fermented maize gruel) and *tombran* (mixed cereal and nut pudding).

257 **3.2 Occurrence of mycotoxins in breast milk**

258 Breast milk samples were examined for the presence of 34 mycotoxins (or their
259 metabolites), of which nine were observed. All 22 breast milk samples contained mycotoxins
260 although mostly at very low concentrations (Table 2). The most frequently detected mycotoxins
261 were BEA (incidence: 100%; range: 1.0–12.0 ng/L; mean: 3.0 ng/L) and AME (incidence: 96%;
262 range: 0.5–11.7 ng/L; mean: 3.0 ng/L), whereas DHC (incidence: 27%; range: 14.0–59.7 ng/L;
263 mean: 25.2 ng/L) and OTA (incidence: 64%; range: 2.0–67.6 ng/L; mean: 9.6 ng/L) had higher
264 mean levels than all other mycotoxins found in the samples. AFM₁ was the only aflatoxin
265 metabolite detected in breast milk, occurring in 18% of the samples at levels below the LOQ;
266 thus, the data points were assigned LOQ/2 values of 2.0 ng/L (Table 2). Enniatins (EnnB and
267 EnnB₁) occurred in 77% of the samples, with EnnB dominating in 73% of samples at mean
268 concentration of 5.0 ng/L (range: 0.7–10.1 ng/L). Sterigmatocystin (STER) was detected in one
269 sample at 1.2 ng/L. The chromatograms of DHC and STER detected in breast milk are shown in
270 Figure 1 (C–D).

271 **3.3 Distribution of mycotoxins in plate-ready complementary food**

272 Sixty-five fungal metabolites, of which 14 were mycotoxins (Table 3), and 25 other
273 secondary metabolites (Table S1) were quantified in the samples of plate-ready complementary
274 food. Aflatoxin B₁, B₂ and G₁ were detected, but not AFG₂. Total AFs contaminated 21% of food
275 samples of which the mean was 6.0 µg/kg (range: 1.0–16.2 µg/kg). The mean level of AFG₁ (12
276 µg/kg) deriving from two *ogi* samples was three-fold higher than that of AFB₁ (3 µg/kg). The

277 incidence of FUM (sum of fumonisins B series (B₁ and B₂) was 29%, of which the mean was:
278 48.8 µg/kg (range 7.9–194 µg/kg). BEA (incidence: 79%; mean: 3.8 µg/kg) was the most
279 frequently detected mycotoxin in the food samples. Enniatins, ZEN, MON and DON also
280 occurred in 19, 10, 7 and 5% of the foods, respectively. With respect to occurrence of the toxins
281 in food types, the highest mean concentrations of BEA (19.4 µg/kg), enniatins (9.6 µg/kg) and
282 FUM (63.1 µg/kg), were found in infant cereal. Of the three food types, *ogi* contained the highest
283 mean levels of AF (6.5 µg/kg) and DON (61.5 µg/kg). AF and MON were not found in infant
284 cereal. *Ogi* and *tombran* contained more diverse mycotoxins than infant cereal (Table 3).

285 **3.4 Mycotoxins in urines of infants**

286 **3.4.1 Overview of the distribution of mycotoxins in infant urines**

287 At least one mycotoxin was detected in 64/65 (99%) of the urine samples, with 10
288 distinct mycotoxins observed, including aflatoxins (AFM₁ and AFQ₁), fumonisin B₁, DON, DHC,
289 NIV, OTA, zearalenones (ZEN, α-ZEL, and β-ZEL), representing seven classes of mycotoxin
290 (Table 4). The detected aflatoxins were two metabolites: AFM₁ (6/65, 9% of samples; mean of
291 detected (MoD): 140 ng/L; range: 23–505 ng/L) and AFQ₁ (44/65, 68% of samples; MoD: 210
292 ng/L; range: 3–898 ng/L). Two infants had only AFM₁ detected, with no AFQ₁, thus in total 46/65
293 (71%) of the infants had been exposed to dietary aflatoxin. Only one of the fumonisin class of
294 mycotoxins was detected, FB₁ (17/65, 26% of samples; MoD: 380 ng/L; range: 35–1587 ng/L).
295 OTA, ZEN, DON and DHC were also frequently detected (Table 4). The chromatograms of
296 AFQ₁ and DHC detected in urine are given in Figure 1(A–B). Mycotoxins in urine were higher in
297 females versus males, though no statistically significant differences in frequency or
298 concentration for individual toxins was observed (data not shown).

299

300 **3.4.2 Mycotoxins in exclusively breastfed (EB) and non-exclusively breastfed (NEB) infants'** 301 **urine**

302 Eight of the 10 mycotoxins were observed frequently in NEB infants compared to EB
303 infants: AFM₁ (12 vs 4%), DON (55 vs 30%), DHC (74 vs 26%), FB₁ (31 vs 17%), OTA (38 vs
304 26%), ZEN (83 vs 57%), respectively, and NIV and α -ZEL which were only detected in NEB
305 infants' urine (Table 4). The recorded detection frequencies of the mycotoxins resulted in a 46–
306 300% increase from EB to NEB cohorts (Figure 2). There were however reductions in the
307 frequencies of detection for AFQ₁ (NEB: 53 vs EB: 87%) and β -ZEL (NEB: 14 vs EB: 30%). The
308 mean concentrations in urine with detectable mycotoxins were higher, for seven of the 10
309 mycotoxins, in NEB versus EB infants: AFM₁ (166 vs 23 ng/L), AFQ₁ (225 vs 182 ng/L), DON
310 (5,282 vs 3,194 ng/L), DHC (202 vs 135 ng/L), FB₁ (454 vs 136 ng/L), NIV (161 ng/L vs non-
311 detect) and α -ZEL (20 ng/L vs non-detect), respectively, see Table 4; resulting in 124–721%
312 increase (Figure 2). However, significant ($p<0.05$) higher mean levels were only recorded for
313 AFQ₁, DON, DHC and FB₁ in favour of NEB infants, and for OTA in favour of EB infants (Table
314 4).

315 **3.5 Mycotoxin co-occurrence and co-exposures**

316 The numbers of different classes of mycotoxins detected in each of breast milk,
317 complementary food and urine were determined (Table 5). All breast milk samples contained
318 more than one and up to five mycotoxin classes; 41% of samples had four or more different
319 mycotoxins detected, though overall mycotoxin concentrations were low. The primary
320 combinations in the mycotoxin mixtures in breast milk included AME, BEA, enniatins and OTA.
321 Aflatoxins were observed as part of 4/22 (18%) mixtures of toxins. Fumonisin in breast milk
322 were not measured in the present study.

323 Mycotoxin mixtures, of 2–5 toxins, were observed in just over half (22/42; 52%) of the
324 plate-ready complementary food samples. The observed mixtures in the complementary food
325 samples predominantly involved three classes of mycotoxins: BEA in 12 mixtures, FUM in nine
326 mixtures and AF in eight mixtures. Of these mixtures, five samples with three or more toxins
327 contained both AF and FUM.

328 Mixtures of 2–6 mycotoxins were observed in about 86% of the urines, with NEB
329 typically having more urine samples with mixtures (93%, with 2–6 toxins) compared to EB
330 infants (74% with 2–5 toxins). The most frequently occurring classes of toxins in mixtures were
331 ZEN (45/65; 69%), AF (42/65; 65%), DHC (41/65; 63%) and DON (30/65; 46%). AF and FUM in
332 the same urine occurred in 13/65 (20%). One infant from the NEB cohort was co-exposed to
333 seven mycotoxins and metabolites belonging to six of the assessed mycotoxin classes except
334 NIV (Figure 3).

335 Paired frequencies of mycotoxin detected in the matrices from each cohort were
336 compared. In the EB cohort, contamination frequencies in breast milk and urine were
337 AFM₁/AFM₁ (18%/4%), AFM₁/AFQ₁ (18%/87%), DHC (27%/26%) and OTA (64%/26%). The
338 contamination frequencies in complementary food vs urine in the NEB cohort were AFB₁/AFM₁
339 (27%/12%), AFB₁/AFQ₁ (27%/57%), DON (5%/55%), FB₁ (29%/31%) and ZEN (10%/83%).

340

341 **4. Discussion**

342 Infants' transition from breastfeeding to complementary food is an essential nutritional
343 requirement. However, it is important to understand if this transition creates opportunities for
344 differential exposure to diverse classes of fungal toxins and also other food and environmental
345 contaminants (i.e., the exposome). The diversity of mycotoxins in breast milk is still in the
346 exploratory stage, though several mycotoxins have been observed, most notably aflatoxins;
347 however, food measurements are by far more established to date despite several limitations
348 (IARC, 2012a, 2012b, 2015). This study provides a measure of multiple mycotoxins in both
349 breast milk and plate-ready complementary foods, and then compares patterns of these
350 mycotoxins in urine from infants that are either EB or partially receiving breast milk and
351 complementary foods, NEB.

352 In this study, the analytical sensitivity for measuring mycotoxins in breast milk was
353 extremely high (low LOD), and thus the frequency of toxin detection was quite high, providing
354 unique insights into chronic background level exposure patterns. All 22 samples had two or
355 more toxins, though overall the concentrations would be regarded as low. The lipophilic
356 aflatoxins such as AFB₁ or AFG₁ are commonly detected in grains in sub-Saharan Africa
357 (Ezekiel et al., 2018a), but were not observed in breastmilk. The AFB₁ metabolite, AFM₁, was
358 observed in four samples and at a level below the LOQ (4 ng/L). This data suggests that breast
359 milk is not providing significant exposure to the most carcinogenic of the mycotoxins for
360 participants of this study. AFM₁ in breast milk occurred at lower mean concentrations than those
361 previously reported from Sierra Leone (800 ng/L, Jonsyn et al., 1995), Egypt (60 ng/L,
362 Polychronaki et al., 2007), Nigeria (35 ng/L, Adejumo et al., 2013) and Ecuador (45 ng/L, Ortiz
363 et al., 2018), but similar to levels reported in two samples from Brazil (0.3 and 0.8 ng/L, Iha et
364 al., 2014).

365 Prior to the present study, there were no reports on the occurrence of CIT and its
366 metabolites as well as STER in human breast milk (Ali and Degen, 2019; Cherkani-Hassani et
367 al., 2016; Warth et al., 2016). Thus, to the best of our knowledge, we present the first report of
368 DHC and STER occurrences in human breast milk. DHC, mostly considered a detoxification
369 product of CIT but also co-detected with CIT in food samples (Ezekiel et al., 2020; Ojuri et al.,
370 2018, 2019), is indicative of CIT exposure (Ali and Degen, 2019; Follmann et al., 2014). The
371 concentrations of DHC in breast milk samples analyzed in the present study were low, and as
372 much as 10 times lower than the concentrations found in urine. However, the presence of DHC
373 in both biological fluids compel us to hypothesize that CIT intake is common in Nigeria (Akinfala
374 et al., 2020; Ezekiel et al., 2020; Ojuri et al., 2018, 2019). Furthermore, it agrees with the
375 suggestions of Ali and Degen (2019) who retrospectively estimated high CIT exposure
376 assessment/intake above the “level of no concern for nephrotoxicity” of 0.2 µg/kg bwt/day set by
377 EFSA (EC, 2014; EFSA, 2012) in participants in a previous urinary biomarker study in Nigeria

378 (Šarkanj et al., 2018). Due to sparse data on its occurrence and toxicity, there is no regulation
379 on maximum levels (ML) of STER in food, including infant diets, in most countries, Nigeria
380 inclusive (EC, 2006; Oplatowska-Stachowiak et al., 2018). Nonetheless, this mycotoxin may be
381 carcinogenic in humans (EFSA, 2013; IARC, 1987), as such, its detection in breast milk
382 samples provides a basis for the consideration of more investigations into the occurrence and
383 regulation of this mycotoxin in foods intended for infants and young children.

384 The mean level of the nephrotoxic OTA in the analyzed breast milk was 50 times lower
385 than the maximum tolerable limit of 500 ng/L set for infant food in Europe (EC, 2006).
386 Additionally, the recorded level was four to five times lower than those reported in Chile (mean:
387 44 ng/L, Munoz et al., 2014) and Bolivia (mean: 53 ng/L, Ferrufino-Guardia et al., 2019) but
388 nearly two times higher than the mean level reported in Italy (mean: 6.0 ng/L, Turconi et al.,
389 2004). The identification of BEA and EnnB in human breast milk agrees with previous reports
390 from Spain (Rubert et al., 2014) and Nigeria (Braun et al., 2018). The mean concentration of
391 AME in the present study is, however, lower than the mean level (11.5 ng/L) in a previous study
392 from Nigeria (Braun et al., 2020). Due to poor analytical recoveries at the outset, fumonisins
393 were not included in the breast milk analysis. The observed variations in mycotoxin levels in
394 breast milk from our study compared to previous reports may be due to any or several of these
395 factors: differences in study population (geography and size), dietary patterns, metabolic status
396 of mothers, lactation stage, or even the uncertainty related to comparing data from distinct
397 analytical methods .

398 Mycotoxins have been previously reported in complementary foods (Cappozzo et al.,
399 2017; Chuisseu Njamen et al., 2018; Juan et al., 2014; Kamala et al., 2016; Kolakowski et al.,
400 2016; Ojuri et al., 2018, 2019; Oueslati et al., 2018). The detection of more diverse spectra of
401 mycotoxins (AF, BEA, EnnB, FUM, MON and ZEN) in the traditionally processed
402 complementary foods (*ogi* and *tombran*) compared to the industrially processed infant cereal
403 agrees with an earlier report from our group on mycotoxins in complementary foods from

404 Nigeria (Ojuri et al., 2018, 2019). AFs were detected in about 20% of the food samples, but
405 notably not in the infant cereal. The mean of these samples with detectable AFs in traditionally
406 processed complementary foods exceeded the 4 µg/kg maximum level for total AF in Nigerian
407 baby food (Ojuri et al., 2018). The presence of AF in locally processed complementary foods but
408 not in commercial infant cereal is in keeping with the report from Cameroon (Chuisseu Njamen
409 et al., 2018). However, the levels found in the present study were lower than those previously
410 reported in locally processed baby foods from Cameroon (mean: 177 µg/kg, Chuisseu Njamen
411 et al., 2018) and Nigeria (mean: 104 µg/kg, Ojuri et al., 2018), but similar to Ghana (mean: 8.3
412 µg/kg, Blankson et al., 2019). Unlike most of the aforementioned reports, herein we analyzed
413 plate-ready food for a more precise food contamination data because it considers food ingested
414 after final preparatory steps such as dilution and cooking (Chuisseu Njamen et al., 2018; Ezekiel
415 et al., 2019). Clearly, the methods employed at household levels, often characterized by poor
416 food processing practices, influenced the mycotoxin contents in the traditionally processed
417 complementary foods. The fact that we could not detect AF in the infant cereal could be
418 attributed to tailoring of production by industrial processors to meet regulatory standards for AF.

419 FUM was detected in all the complementary food types. However, the mean
420 concentrations we found were lower than the European Union ML of 200 µg/kg for baby food
421 (EC, 2006) and the mean level (2808 µg/kg) reported in Tanzania (Kamala et al., 2016). FUM is
422 not regulated in baby foods in Nigeria. Nevertheless, the observed co-occurrence of FUM with
423 AF in about 20% of the complementary foods is of concern, because these two mycotoxins are
424 suggested to negatively influence linear growth in children (IARC, 2015; Shirima et al., 2015).
425 Meanwhile, a potential role of additional toxins in mixtures is unknown.

426 Several mycotoxins were detected in the children's urine similar to previous reports from
427 Cameroon (Ediage et al., 2013), Nigeria (Ezekiel et al., 2014), Spain (Rodriguez-Carrasco et al.,
428 2014) and Belgium (Heyndrickx et al., 2015) where the simultaneous exposure to more than two
429 mycotoxins were detected. The incidences and analytical concentrations of commonly found

430 mycotoxins in children urine were compared with data from previous studies. Overall, ZEN
431 (incidence: 74%), a potent estrogenic mycotoxin (IARC 2012b, 2015), was the most frequently
432 detected mycotoxin in the urine samples. Two ZEN metabolites, α -ZEL and β -ZEL, were
433 detected in the urine samples albeit at lower frequencies (11% and 20%, respectively)
434 compared to the parent compound. This is in contrast to the reports of Heyndrickx et al. (2015)
435 wherein ZEN and its metabolites were not detected in children urine from Belgium. The
436 incidence of ZEN in the present study was, however, higher than the incidence (4%, 9/220)
437 previously reported in Cameroonian children employing a method of lower sensitivity, whereas
438 the mean level was higher in the Cameroonian children (970 ng/L) (Ediage et al., 2013) than in
439 the present study (142 ng/L). Similarly, the incidence of DHC in the present study (57%, 37/65)
440 was higher, although with a lower mean concentration of 212 ng/L, than the 14% (20/142)
441 incidence and mean of 490 ng/L reported in urine of adults and children in Haiti (Gerding et al.,
442 2015). Additionally, the incidence of DHC in the present study was much higher than the 6%
443 (7/124) incidence reported for DHC in urine of Belgian children (Heyndrickx et al., 2015). The
444 parent toxin CIT was not detected in any urine sample, which agrees with the reports from Haiti
445 but negates the Belgian study that found both parent compound (CIT) and its metabolite (DHC).
446 Regardless, the higher incidence of DHC recorded in the present study further suggests that
447 CIT exposure is widespread in Nigerian children. DON (46%, 30/65) occurrence in urine in the
448 present study was lower than those previously reported in adults from France (99%, 75/76,
449 Turner et al., 2010), pregnant women (100%, 85/85, Hepworth et al., 2012) and children in the
450 United Kingdom (100%, 40/40, Papageorgiou et al., 2018; 100%, 21/21, Gratz et al., 2020), but
451 more similar to in the reports from Egypt (68%, 63/93, Piekkola et al., 2012) and Iran (72%,
452 79/110, Turner et al., 2012b). Infant data on DON in urine are mostly lacking. In the present
453 study, urinary OTA (34%, 22/65; mean: 14 ng/L) was lower than the previous report in
454 Portuguese children (93%, 79/85; mean: 20 ng/L) (Silva et al., 2019). Similarly, urinary FB₁
455 incidence of 26% (17/65) recorded in the present study was lower than the 96% incidence

456 reported in a study comprising 147 Tanzanian children's urine (Shirima et al., 2013) but was
457 higher than the incidence (2%, 1/50) reported in Nepalese children (Mitchell et al., 2016).

458 To date, AFM₁ has been the most reported urinary AF metabolite and biomarker in
459 children (Ayelign et al., 2017; Chen et al., 2017; Ediage et al., 2013; Ezekiel et al., 2014;
460 Gerding et al., 2015; Polychronaki et al., 2008; Sanchez and Diaz, 2019; Schwartzbord et al.,
461 2016). However, in the present study, AFQ₁ was found to be the major aflatoxin metabolite (both
462 in frequency and concentration), occurring in 44/65 (68%) of the children's urine samples,
463 whereas AFM₁ was detected in 6/65 (9%) of urine samples, four of which had both AFM₁ and
464 AFQ₁. Previous reports on AFQ₁ occurrence in human urine were on adolescents and adults
465 15–64 years of age in China and The Gambia (Groopman et al., 1992a, 1992b; Mykkanen et al.,
466 2005; Wang et al., 2001). Consequently, to the best of our knowledge, AFQ₁ is reported for the
467 first time in the urine of children in any setting. Urinary AFM₁ and AF-N7-guanine are
468 established biomarkers for aflatoxin exposure; however, these were established in adults
469 (Groopman et al., 1992a). Given the role of CYP3A4 in AFQ₁ formation (Wild and Turner,
470 2002) and the known significant ontogeny in xenobiotic metabolizing enzymes (Blake et al.,
471 2005), involved in AFB₁ biotransformation, it would be useful to better understand the
472 relationship between dose and the various metabolites of aflatoxins in urine of infants.
473 Nevertheless, the recorded higher incidence of AFQ₁ in the urine samples compared with AFM₁
474 informs us that aflatoxin exposure in young children may be underreported.

475 Comparing the two cohorts of infants, higher mean levels of seven out of the 10 detected
476 mycotoxins were found in the NEB urine compared to the EB urine, with statistically significant
477 levels recorded for four of these mycotoxins including AFQ₁, DON, DHC and FB₁. Notably,
478 increases in the mean mycotoxin levels in urine moving from EB regime to the NEB regime
479 reached 721 and 334% for AFM₁ and FB₁, respectively. Additionally, the NEB cohort generally
480 recorded higher diversities of mycotoxin mixtures in urine compared to the EB cohort. Here, we
481 show that transition from EB to NEB, involving a change in diet, modulates contaminant

482 exposure resulting in a large variation of multiple mycotoxin exposures in infants. This primarily
483 owes to the higher intake of complementary foods, which are usually made from mycotoxin-
484 prone cereals, nuts and oil seeds (Chuisseu Njamen et al., 2018; Juan et al., 2014; Kamala et
485 al., 2016; Kimanya et al., 2009; 2010, 2014; Ojuri et al., 2018, 2019; Okeke et al., 2015). These
486 observations are strongly suggestive that exclusive breastfeeding provides a relatively, but not
487 completely, protected period from mycotoxin exposure.

488 The spectra and combinations of mycotoxins detected in the three specimens examined
489 in this study further suggest frequent exposure in Nigerian children, especially in the NEB
490 category. Obviously, urine contained higher number of mycotoxins and their mixtures compared
491 to complementary foods and breast milk. Comparison of the paired contamination frequencies in
492 both cohorts, especially in the NEB, favored urine with higher frequencies detected for
493 aflatoxins, FB₁ and ZEN compared to complementary foods. Further, some mycotoxins occurred
494 only in the biological fluids reiterating the importance of preferring biomonitoring approaches
495 over food contamination data for exposure assessment in humans (Ali and Degen, 2019; Turner
496 et al., 2012; Vidal et al., 2018; Warth et al., 2013). A typical example is DHC and OTA that were
497 detected only in the biological fluids (breast milk for the EB group and urine from both cohorts).
498 Although CIT/DHC was not detected in the examined complementary foods in the present
499 study, it was found in 74% of the urines of EB children. We did not sample milk for the NEB
500 cohort due to reluctance in provision of milk by mothers in this group; nevertheless, it is possible
501 that the DHC levels in the urines of both cohorts originated from the lactating mothers' milk
502 since this metabolite or its parent toxin was not found in the complementary food. CIT levels in
503 grains (especially maize) and complementary food in Nigeria have recently been shown to be
504 high reaching 16,000 µg/kg (Ezekiel et al., 2020; Ojuri et al., 2018, 2019; Okeke et al., 2015,
505 2018). Fermented cocoa beans in Nigeria, which could also be processed and used in the
506 preparation of foods for mothers as well as for infants and young children, have also recently
507 been reported to contain CIT (Akinfala et al., 2020). Put together, only aflatoxins, DHC and OTA

508 were found in both breast milk and urine of the EB cohort, while aflatoxins, DON, FB₁ and ZEN
509 were detected in both complementary food and NEB children's urine.

510 An additional important finding was the detection of BEA and EnnB in complementary
511 food and breast milk but not in urine because the urinary analytical method did not include both
512 mycotoxins. EnnB was recently detected in adult human urine from Italy (Rodriguez-Carrasco et
513 al., 2018); however, there is limited data on urinary BEA and EnnB in children. Considering the
514 widespread detection of BEA and EnnB in foods in Nigeria, albeit at low concentrations (Abdus-
515 Salaam et al., 2015; Adetunji et al., 2014; Ezekiel et al., 2016; Ojuri et al., 2018; Oyedele et al.,
516 2017), and the documented *in vitro* data suggesting their roles in decreasing immune response
517 to infections (Ficheux et al., 2013) as well as their interactions to cause additive myelotoxicity
518 (Ficheux et al., 2012), the inclusion of both mycotoxins in future urinary biomonitoring studies,
519 especially for children, is recommended.

520 In this study, the levels of any given mycotoxin were typically modest compared to
521 studies where associations with an individual mycotoxin and a given health outcome, e.g.,
522 stunting, was reported (IARC, 2015). However, the study reveals a clear transition in exposure
523 from EB to NEB infants in terms of both level and frequency to mixtures. The overall health
524 implication for children in the study region was not measured. Focusing on infant growth, *in vitro*
525 studies using human intestinal cell lines revealed that DON selectively modulated intestinal
526 transporters (Maresca et al., 2002) while FB₁ decreased intestinal cell viability and proliferation
527 (Minervini et al., 2014). Consequently, these mycotoxins may play interactive roles to affect
528 nutrient absorption (Liew and Mohd-Redzwan, 2018) which may cumulatively contribute to AF
529 induced growth faltering. Thus, future studies may consider exploring the type and extent of
530 interactive effects the various recorded mixtures may have on this highly vulnerable population
531 and their growth into adulthood.

532

533 **5. Conclusion**

534 This study provides a comprehensive account on and novel insights into multiple
535 mycotoxin exposures in EB and NEB infants in a high-risk country, Nigeria, based on
536 examination of three specimens (breast milk, complementary food and urine). One pitfall of this
537 study is the non-collection of breast milk for the NEB cohort, leaving the conclusions on NEB
538 cohort anchored more on the urine data, which served as a comparative matrix for both EB and
539 NEB cohorts. However, data for breast milk from EB cohort suggested that no significant
540 exposure to the most carcinogenic mycotoxins was recorded. Consequently, we report the
541 presence of several uncommon mycotoxins in biological fluids (DHC and STER in breast milk;
542 and AFQ₁, being the dominant urinary aflatoxin metabolite). The higher incidence of AFQ₁ in
543 infant urine compared with AFM₁ suggests that aflatoxin exposure in young children may be
544 underreported. Second, the presence of up to six distinct mycotoxin classes are reported for the
545 first time in breast milk and infant urine. Third, urines of NEB infants contained higher levels of
546 mycotoxins and several mixtures of these toxins more frequently than in urines of EB infants.
547 Thus, exposure to mycotoxins for infants less than 18 months of age is common in the region,
548 with a significant transition in higher frequency and levels of exposure with the introduction of
549 complementary foods. Consequently, it is recommended that mothers adhere strictly to
550 measures with potential to reduce mycotoxin contamination in household diets; including
551 maintaining compliance to WHO recommendations for exclusive breastfeeding for 6 months.
552 Once foods are being introduced, adequate drying and proper storage of grains in airtight
553 containers at household levels, sorting out of moldy, damaged and discolored grains prior to
554 meal preparation, and diet diversification to include less mycotoxin prone food crops such as
555 tubers are advised. In addition, prioritizing partnerships focused on driving interventions to
556 mitigate exposures in vulnerable populations is important. Furthermore, attempts to investigate
557 mycotoxin exposure and toxicity holistically in the context of the exposome and DOHaD
558 paradigm should be encouraged.

559

560 **Conflict of interest**

561 Authors do not have any conflict to declare.

562

563 **Acknowledgements**

564 Authors are thankful to Chidinma Akwarandu and Linda Ogu for their assistance during sample
565 collection, and Xiaomin Han, during urine sample preparation. Families who donated samples
566 are deeply appreciated. The authors want to gratefully acknowledge the Mass Spectrometry
567 Centre (MSC) of the Faculty of Chemistry at the University of Vienna and Sciex for providing
568 mass spectrometric instrumentation to BW. This work was performed with the financial support
569 of the University of Vienna, the City of Vienna Jubilee Funds (BOKU Research Funding, project
570 MycoMarker) and the Austrian Science Fund (FWF): P 33188-B.

571

572 **References**

573 Abdus-Salaam, R.S., Fanelli, F., Atanda, O., Sulyok, M., Cozzi, G., Bavaro, S., et al., 2015.
574 Fungal and bacterial metabolites associated with natural contamination of locally
575 processed rice (*Oryza sativa* L.) in Nigeria. *Food Addit. Contam. Part A*. 32(6), 950–959.
576 <https://doi.org/10.1080/19440049.2015.1027880>.

577 Adejumo, O., Atanda, O., Raiola, A., Somorin, Y., Bandyopadhyay, R., Ritieni, A., 2013.
578 Correlation between aflatoxin M₁ content of breast milk, dietary exposure to aflatoxin B₁
579 and socioeconomic status of lactating mothers in Ogun state, Nigeria. *Food Chem.*
580 *Toxicol.* 56, 171–177. <https://doi.org/10.1016/j.fct.2013.02.027>.

581 Adetunji, M., Atanda, O., Ezekiel, C., Sulyok, M., Warth, B., Beltran, E., et al., 2014. Fungal and
582 bacterial metabolites of stored maize (*Zea mays*, L.) from five agro-ecological zones of
583 Nigeria. *Mycotoxin Res.* 30, 89–102. <https://doi.org/10.1007/s12550-014-0194-2>.

584 Aichinger, G., Kruger, F., Puntischer, H., Preindl, K., Warth, B., Marko, D., 2019. Naturally
585 occurring mixtures of *Alternaria* toxins: anti-estrogenic and genotoxic effects *in vitro*.
586 *Arch. Toxicol.* 93(10), 3021–3031. <https://doi.org/10.1007/s00204-019-02545-z>.

- 587 Akinfala, T.O., Houbraken, J., Sulyok, M., Adediji, A.R., Odebode, A.C., Krska, R., et al., 2020.
588 Moulds and their secondary metabolites associated with the fermentation and storage of
589 two cocoa bean hybrids in Nigeria. *Int. J. Food Microbiol.* 316, 108490. <https://doi.org/10.1016/j.ijfoodmicro.2019.108490>
590
- 591 Ali, N., Degen, G.H., 2019. Citrinin biomarkers: a review of recent data and application to
592 human exposure assessment. *Arch. Toxicol.* 93(11), 3057–3066.
593 <https://doi.org/10.1007/s00204-019-02570-y>.
- 594 Alvito, P.C., Sizoo, E.A., Almeida, C.M.M., Egmond, H.P.V., 2010. Occurrence of aflatoxins and
595 ochratoxin A in baby foods in Portugal. *Food Anal. Methods*, 3, 22–30.
596 <https://doi.org/10.1007/s12161-008-9064-x>.
- 597 Ayelign, A., Woldegiorgis, A.Z., Adish, A., De Boevre, M., Heyndrickx, E., De Saeger, S.,
598 2017. Assessment of aflatoxin exposure among young children in Ethiopia using urinary
599 biomarkers. *Food Addit. Contam. Part A.* 34(9), 1606–1616.
600 <https://doi.org/10.1080/19440049.2017.1350290>.
- 601 Barker, D.P.J., 2000. Fetal programming: influences on development and disease in later life, in:
602 Dekker M. (Eds.), *NIH Monograph Series*. New York.
- 603 Bateson, P., Barker, D., Clutton-Brock, T., Deb, D., D'Udine, B., Foley, R.A., et al., 2004.
604 Developmental plasticity and human health. *Nature.* 430, 419–421.
605 <https://doi.org/10.1038/nature02725>.
- 606 Blake, M.J., Castro, L., Leeder, J.S., Kerans, G.L., 2005. Ontogeny of drug metabolizing
607 enzymes in the neonate. *Semin. Fetal Neonatal Med.* 10(2), 123–138.
608 <https://doi.org/10.1016/j.siny.2004.11.001>.
- 609 Blankson, G.K., Mills-Robertson, F.C., Ofofu, I.W., 2019. Survey of occurrence levels of
610 aflatoxins in selected locally processed cereal-based foods for human consumption from
611 Ghana. *Food Contr.* 95, 170–175. <https://doi.org/10.1016/j.foodcont.2018.08.005>.
- 612 Braun, D., Ezekiel, C.N., Abia, W.A., Wisgrill, L., Degen, G.H., Turner, P.C., et al., 2018.
613 Monitoring early-life mycotoxin exposures via LC-MS/MS breast milk analysis. *Anal.*
614 *Chem.* 90, 14569–14577. <https://doi.org/10.1021/acs.analchem.8b04576>.

- 615 Braun, D., Ezekiel, C.N., Marko, D., Warth, B., 2020. Exposure to mycotoxin-mixtures via breast
616 milk: an ultra-sensitive LC-MS/MS biomonitoring approach. *Front. Chem.* 8, 423.
617 <https://doi.org/10.3389/fchem.2020.00423>.
- 618 Butts, C.A., Hedderley, D.I., Herath, T.D., Paturi, G., Glyn-Jones, S., Wiens, F., et al., 2018.
619 Human milk composition and dietary intakes of breastfeeding women of different
620 ethnicity from the Manawatu Wanganui region of New Zealand. *Nutrients.* 10, 1231.
621 <https://doi.org/10.3390/nu10091231>.
- 622 Cappozzo, J., Jackson, L., Lee, H.J., Zhou, W., Al-Taher, F., Zweigenbaum, J., et al.,
623 2017. Occurrence of ochratoxin A in infant foods in the United States. *J. Food Prot.*
624 80(2), 251–256. <https://doi.org/10.4315/0362-028X.JFP-16-339>.
- 625 Chen, G., Gong, Y.Y., Kimanya, M.E., Shirima, C.P., Routledge, M.N., 2017. Comparison of
626 urinary aflatoxin M₁ and aflatoxin albumin adducts as biomarkers for assessing aflatoxin
627 exposure in Tanzanian children. *Biomarkers.* 23(2), 131–136.
628 <https://doi.org/10.1080/1354750X.2017.1285960>.
- 629 Cherkani-Hassani, A., Mojemmi, B., Mouane, N., 2016. Occurrence and levels of mycotoxins
630 and their metabolites in human breast milk associated to dietary habits and other factors:
631 A systematic literature review, 1984–2015. *Trends Food Sci. Technol.* 50, 56–69.
632 <https://doi.org/10.1016/j.tifs.2016.01.024>.
- 633 Chuisseu Djamien, D.P., Abia, W.A., Zibi, S.B., Kuo, N.S., Ngantchouko Ngalemo, C.B., Tambo,
634 E., et al., 2018. Safety of breast milk vis-à-vis common infant formula and
635 complementary foods from mycotoxin perspective. *Recent Adv. Food Sci.* 1(1), 23–31.
- 636 Chu, F.S., Li, G.Y., 1994. Simultaneous occurrence of fumonisin B₁ and other mycotoxins in
637 moldy corn collected from the People's Republic of China in regions with high incidences
638 of esophageal cancer. *Appl. Environ. Microbiol.* 60, 847–852.
- 639 EC (European Commission), 2002. Commission Decision 2002/657 of 12 August 2002
640 implementing Council Directive 96/23/EC concerning the performance of analytical
641 methods and the interpretation of results. *Off. J. Euro. Union L.* 221, 8–36.
- 642 EC (European Commission), 2006. Commission regulation (EC) No 1881/2006 of 19 December
643 2006 setting maximum levels for certain contaminants in foodstuffs. *Off. J. Euro. Union,*
644 364, 5–24. Available at <https://eur-lex.europa.eu/>. Accessed 01/ 02/2020.

- 645 EC (European Commission), 2014. Commission regulation (EU) No 212/2014 of 6 March 2014
646 amending Regulation (EC) No 1881/2006 as regards maximum levels of the
647 contaminant citrinin in food supplements based on rice fermented with red yeast
648 *Monascus purpureus*. Available at <http://faolex.fao.org/docs/pdf/eur131703.pdf>.
649 Accessed on 01/02/2020.
- 650 Ediage, E.N., Diana Di Mavungu, J., Song, S., Sioen, I., De Saeger, S., 2013. Multimycotoxin
651 analysis in urines to assess infant exposure: a case study in Cameroon. *Environ. Int.*
652 57–58, 50–59. <https://doi.org/10.1016/j.envint.2013.04.002>.
- 653 EFSA (European Food Safety Authority), 2012. Scientific opinion on the risks for public and
654 animal health related to the presence of citrinin in food and feed. *EFSA J.* 10, 2605.
655 <https://doi.org/10.2903/j.efsa.2012.2605>.
- 656 EFSA (European Food Safety Authority). 2013. Scientific opinion on the risk for public and
657 animal health related to the presence of sterigmatocystin in food and feed. *EFSA J.*
658 11(6), 3254. <https://doi.org/10.2903/j.efsa.2013.3254>.
- 659 Ezekiel, C.N., Ayeni, K.I., Misihairabgwi, J.M., Somorin, Y.M., Chibuzor-Onyema, I.E., Oyedele,
660 O.A., et al., 2018a. Traditionally processed beverages in Africa: A review of the
661 mycotoxin occurrence patterns and exposure assessment. *Compr. Rev. Food Sci. Food*
662 *Saf.* 17(2), 334–351, <https://doi.org/10.1111/1541-4337.12329>.
- 663 Ezekiel, C.N., Oyedele, O.A., Kraak, B., Ayeni, K.I., Sulyok, M., Houbraken, J., et al., 2020.
664 Fungal diversity and mycotoxins in low moisture content ready-to-eat foods in Nigeria.
665 *Front. Microbiol.* 11, 615. <https://doi.org/10.3389/fmicb.2020.00615>.
- 666 Ezekiel, C.N., Oyeyemi, O.T., Oyedele, O.A., Ayeni, K.I., Oyeyemi, I.T., Nabofa, W., et al.,
667 2018b. Urinary aflatoxin exposure monitoring in rural and semi-urban populations in
668 Ogun state, Nigeria. *Food Addit. Contam. Part A.* 35(8), 1565–1572.
669 <https://doi.org/10.1080/19440049.2018.1475752>.
- 670 Ezekiel, C.N., Sulyok, M., Ogara, I.M., Abia, W.A., Warth, B., Šarkanj, B., et al.,
671 2019. Mycotoxins in uncooked and plate-ready household food from rural northern
672 Nigeria. *Food Chem. Toxicol.* 128, 171–179. <https://doi.org/10.1016/j.fct.2019.04.002>.
- 673 Ezekiel, C.N., Sulyok, M., Somorin, Y., Odutayo, F.I., Nwabekee, S.U., Balogun, A.F., et al.,
674 2016. Mould and mycotoxin exposure assessment of melon and bush mango seeds, two

- 675 common soup thickeners consumed in Nigeria. *Int. J. Food Microbiol.* 237, 83–91.
676 <https://doi.org/10.1016/j.ijfoodmicro.2016.08.019>.
- 677 Ezekiel, C.N., Warth, B., Ogara, I.M., Abia, W.A., Ezekiel, V.C., Atehnkeng, J., et al.,
678 2014. Mycotoxin exposure in rural residents in northern Nigeria: A pilot study using multi-
679 urinary biomarkers. *Environ. Int.* 66, 138–145.
680 <https://doi.org/10.1016/j.envint.2014.02.003>.
- 681 Ferrufino-Guardia, E., Chavez-Rico, V., Larondelle, Y., 2019. Ochratoxin A in human breast
682 milk, maternal and placental blood from Cochabamba-Bolivia. *Rev. Toxicol.* 36, 116–
683 125.
- 684 Ficheux, A.S., Sibiril, Y., Parent-Massin, D., 2012. Co-exposure of *Fusarium* mycotoxins: *in vitro*
685 myelotoxicity assessment on human hematopoietic progenitors. *Toxicol.* 60(6), 1171–
686 1179. <https://doi.org/10.1016/j.toxicol.2012.08.001>.
- 687 Ficheux, A.S., Sibiril, Y., Parent-Massin, D., 2013. Effects of beauvericin, enniatin B and
688 moniliformin on human dendritic cells and macrophages: An *invitro* study. *Toxicol.* 71,
689 1–10. <https://doi.org/10.1016/j.toxicol.2013.04.024>.
- 690 Gerding, J., Ali, N., Schwartzbord, J., Cramer, B., Brown, D.L., Degen, G.H., Humpf, H.-U.,
691 2015. A comparative study of the human urinary mycotoxin excretion patterns in
692 Bangladesh, Germany, and Haiti using a rapid sensitive LC-MS/MS approach.
693 *Mycotoxin Res.* 31(3), 127–136. <https://doi.org/10.1007/s12550-015-0223-9>.
- 694 Gong, Y.Y., Cardwell, K., Hounsa, A., Egal, S., Turner, P.C., Hall, A.J., et al., 2002. Dietary
695 aflatoxin exposure and impaired growth in young children from Benin and Togo: cross
696 sectional study. *Br. Med. J.* 325, 20–21. <https://doi.org/10.1136/bmj.325.7354.20>.
- 697 Gong, Y.Y., Egal, S., Hounsa, A., Turner, P.C., Hall, A.J., Cardwell, K., et al., 2003.
698 Determinants of aflatoxin exposure in young children from Benin and Togo, West Africa:
699 the critical role of weaning. *Int. J. Epidemiol.* 32, 556–562.
700 <https://doi.org/10.1093/ije/dyg109>.
- 701 Gong, Y., Hounsa, A., Egal, S., Turner, P.C., Sutcliffe, A.E., Hall, A.J., et al., 2004. Postweaning
702 exposure to aflatoxin results in impaired child growth: a longitudinal study in Benin, West
703 Africa. *Environ. Health Perspect.* 112, 1334–1338. <https://doi.org/10.1289/ehp.6954>.

- 704 Gong, Y.Y., Wilson, S., Mwatha, J.K., Routledge, M.N., Castelino, J.M., Zhao, B., et al., 2012.
705 Aflatoxin exposure may contribute to chronic hepatomegaly in Kenyan school children.
706 *Environ. Health Perspect.* 120, 893–896. <https://doi.org/10.1289/ehp.1104357>.
- 707 Gratz, S.W., Currie, V., Duncan, G., Jackson, D., 2020. Multimycotoxin exposure assessment in
708 UK children using urinary biomarkers – a pilot survey. *J Agric. Food Chem.* 68(1), 351–
709 357. <https://doi.org/10.1021/acs.jafc.9b03964>
- 710 Groopman, J.D., Hall, A.J., Whittle, H., Hudson, G.J., Wogan, G.N., Montesano, R., et al.,
711 1992a. Molecular dosimetry of aflatoxin-N7-guanine in human urine obtained in the
712 Gambia, west Africa. *Cancer Epidemiol. Biomarkers Prev.* 1, 221–227.
- 713 Groopman, J.D., Jiaqi, Z., Donahue, P.R., Pikul, A., Lisheng, Z., Jun-shi, C., et al., 1992b.
714 Molecular dosimetry of urinary aflatoxin-DNA adducts in People living in Guangxi
715 autonomous region, People’s Republic of China. *Cancer Res.* 52, 45–52.
- 716 Hepworth, S.J., Hardie, L.J., Fraser, L.K., Burley, V.J., Mijal, R.S., Wild, C.P., et al., 2012.
717 Deoxynivalenol exposure assessment in a cohort of pregnant women from Bradford, UK.
718 *Food Addit. Contam. Part A: Chem. Anal. Control Expo. Risk Assess.* 29(2), 269–276.
719 <https://doi.org/1080/19440049.2010.551301>.
- 720 Heussner, A.H., Bingle, L.E.H., 2015. Comparative ochratoxin toxicity: a review of the available
721 data. *Toxins.* 7(10), 4253–4282. <https://doi.org/10.3390/toxins7104253>.
- 722 Heyndrickx, E., Sioen, I., Huybrechts, B., Callebaut, A., De Henauw, S., De Saeger, S.,
723 2015. Human biomonitoring of multiple mycotoxins in the Belgian population: results of
724 the BIOMYCO study. *Environ. Int.* 84, 82–89.
725 <https://doi.org/10.1016/j.envint.2015.06.011>.
- 726 IARC (International Agency for Research on Cancer), 1987. Some naturally occurring
727 substances. In: IARC monographs on the evaluation of carcinogenic risks to humans.
728 Summaries and evaluations. 10, 72.
- 729 IARC (International Agency for Research on Cancer), 2002. Traditional herbal medicines, some
730 mycotoxins, naphthalene, and styrene. IARC monographs on the evaluation carcinogenic
731 risk to humans. 82, 1–556.

- 732 IARC (International Agency for Research on Cancer), 2012a. Monographs on the evaluation of
733 carcinogenic risks to humans: chemical agents and related occupations. A review of
734 human carcinogens. Lyon, France: 100F, 224–248.
- 735 IARC (International Agency for Research on Cancer), 2012b. Improving public health through
736 mycotoxin control, IARC Scientific publication No. 158, Lyon.
- 737 IARC (International Agency for Research on Cancer). 2015. Mycotoxin control in low- and
738 middle-income countries, IARC Working Group Reports 9, Lyon.
- 739 Iha, M.H., Barbosa, C.B., Heck, A.R., Trucksess, M.W., 2014. Aflatoxin M₁ and ochratoxin A in
740 human milk in Ribeirão Preto-SP, Brazil. *Food Contr.* 40, 310–313.
741 <https://doi.org/10.1016/j.foodcont.2013.12.014>.
- 742 Innis, S.M., 2014. Impact of maternal diet on human milk composition and neurological
743 development of infants. *Am. J. Clin. Nutr.* 99(3), 734S-741S.
744 <https://doi.org/10.3945/ajcn.113.072595>.
- 745 Jonsyn, F.E., Maxwell, S.M., Hendrickse, R.G., 1995. Ochratoxin A and aflatoxins in breast milk
746 samples from Sierra Leone. *Mycopathologia.* 131, 121–126.
747 <https://doi.org/10.1007/BF01102890>.
- 748 Juan, C., Raiola, A., Mães, J., Ritieni, A., 2014. Presence of mycotoxin in commercial infant
749 formulas and baby foods from Italian market. *Food Contr.* 39, 227–236.
750 <https://doi.org/10.1016/j.foodcont.2013.10.036>.
- 751 Kamala, A., Kimanya, M., Lachat, C., Jacxsens, L., Haesaert, G., Kolsteren, P., et al., 2016.
752 Risk of exposure to multiple mycotoxins from maize-based complementary foods in
753 Tanzania. *J. Agr. Food Chem.* 65(33), 7106–7114.
754 <https://doi.org/10.1021/acs.jafc.6b03429>.
- 755 Kimanya, M.E., Meulenaer, B.D., Baert, K., Tiisekwa, B., Camp, J.V., Samapundo, S., et al.,
756 2009. Exposure of infants to fumonisins in maize-based complementary foods in rural
757 Tanzania. *Mol. Nutr. Food Res.* 53, 667–674. <https://doi.org/10.1002/mnfr.200700488>.
- 758 Kimanya, M.E., Meulenaer, B.D., Baert, K., Tiisekwa, B., Camp, J.V., Samapundo, S., et al.,
759 2010. Fumonisin exposure through maize in complementary foods is inversely

- 760 associated with linear growth of infants in Tanzania. *Mol. Nutr. Food Res.* 54, 1659–
761 1667. <https://doi.org/10.1002/mnfr.200900483>.
- 762 Kimanya, M.E., Shirima, C.P., Magoha, H., Shewiyo, D.H., De Meulenaer, B., Kolsteren, P., et
763 al., 2014. Co-exposures of aflatoxins with deoxynivalenol and fumonisins from maize-
764 based complementary foods in Rombo, northern Tanzania. *Food Contr.* 41, 76–81.
765 <https://doi.org/10.1016/j.foodcont.2013.12.034>.
- 766 Kolakowski, B., O'rourke, S.M., Bietlot, H.P., Kurz, K., Aweryn, B., 2016. Ochratoxin A
767 concentrations in a variety of grain-based and non-grain-based foods on the Canadian
768 retail market from 2009 to 2014. *J. Food Prot.* 79(12), 2143–2159.
769 <https://doi.org/10.4315/0362-028X.JFP-16-051>.
- 770 Liew, W.P.P., Mohd-Redzwan, S., 2018. Mycotoxin: Its Impact on gut health and microbiota.
771 *Front. Cell Infect. Microbiol.* 8, 60. <https://doi.org/10.3389/fcimb.2018.00060>.
- 772 Magnusson, B., 2014. "The fitness for purpose of analytical methods: A laboratory guide to
773 method validation and related topics." 2nd. Eurachem,
774 https://www.eurachem.org/images/stories/Guides/pdf/MV_guide_2nd_ed_EN.pdf.
- 775 Mandy, M., Nyirenda, M., 2018. Developmental origins of health and disease: The relevance to
776 developing nations. *Int. Health* 10, 66–70. <https://doi.org/10.1093/inthealth/ihy006>.
- 777 Maresca, M., Mahfoud, R., Garmy, N., Fantini, J., 2002. The mycotoxin deoxynivalenol affects
778 nutrient absorption in human intestinal epithelial cells. *J. Nutr.* 132(9), 2723–2731.
779 <https://doi.org/10.1093/jn/132.9.2723>.
- 780 McMillian, A., Renaud, J.B., Burgess, K.M.N., Orimadegun, A.E., Akinyinka, O.O., Allen, S.J., et
781 al., 2018. Aflatoxin exposure in Nigerian children with severe acute malnutrition. *Food*
782 *Chem. Toxicol.* 111, 356–362. <https://doi.org/10.1016/j.fct.2017.11.030>.
- 783 Minervini, F., Garbetta, A., D'Antuono, I., Cardinali, A., Martino, N.A., Debellis, L., et al.,
784 2014. Toxic mechanisms induced by fumonisin B₁ mycotoxin on human intestinal cell
785 line. *Arch. Environ. Con. Tox.* 67(1), 115–123. [https://doi.org/10.1007/s00244-014-0004-
z](https://doi.org/10.1007/s00244-014-0004-
786 z).
- 787 Missmer, S.A., Suarez, L., Felkner, M., Wang, E., Merrill Jr, A.H., Rothman, K.J., et al., 2006.
788 Exposure to fumonisins and the occurrence of neural tube defects along the Texas–

- 789 Mexico border. Environ. Health Perspect. 114, 237–241.
790 <https://doi.org/10.1289/ehp.8221>.
- 791 Mitchell, N.J., Riley, R.T., Egner, P.A., Groopman, J.D., Wu, F., 2016. Chronic aflatoxin
792 exposure in children living in Bhaktapur, Nepal: extension of the MAL-ED study. J. Exp.
793 Sci. Env. Epid. 27(1), 106–111. <https://doi.org/10.1038/jes.2015.87>.
- 794 Muñoz, K., Blaszkewicz, M., Campos, V., Vega, M., Degen, G.H., 2014. Exposure of infants to
795 ochratoxin A with breast milk. Arch. Toxicol. 88(3), 837–846.
796 <https://doi.org/10.1007/s00204-013-1168-4>.
- 797 Mykkänen, H., Zhu, H., Salminen, E., Juvonen, R.O., Ling, W., Ma, J., et al., 2005. Fecal and
798 urinary excretion of aflatoxin B₁ metabolites (AFQ₁, AFM₁ and AFB-N7-guanine) in
799 young Chinese males. Int. J. Cancer. 115(6), 879–884. <https://doi.org/10.1002/ijc.20951>.
- 800 Ojuri, O.T., Ezekiel, C.N., Eskola, M.K., Šarkanj, B., Babalola, A.D., Sulyok, M., et al., 2019.
801 Mycotoxin co-exposures in infants and young children consuming household and
802 industrially-processed complementary foods in Nigeria and risk management advice.
803 Food Contr. 98, 312–322. <https://doi.org/10.1016/j.foodcont.2018.11.049>.
- 804 Ojuri, O.T., Ezekiel, C.N., Sulyok, M., Ezeokoli, O.T., Oyedele, O.A., Ayeni, K.I., et al., 2018.
805 Assessing the mycotoxicological risk from consumption of complementary foods by
806 infants and young children in Nigeria. Food Chem. Toxicol. 121, 37–50.
807 <https://doi.org/10.1016/j.fct.2018.08.025>.
- 808 Okeke, C.A., Ezekiel, C.N., Nwangburuka, C.C., Sulyok, M., Ezeamagu, C.O., Adeleke, R.A., et
809 al., 2015. Bacterial diversity and mycotoxin reduction during maize fermentation
810 (steeping) for *ogi* production. Front. Microbiol. 6, 1402.
811 <https://doi.org/10.3389/fmicb.2015.01402>.
- 812 Okeke, C.A., Ezekiel, C.N., Sulyok, M., Ogunremi, O.R., Ezeamagu, C.O., Šarkanj, B., et al.,
813 2018. Traditional processing impacts mycotoxin levels and nutritional value of *ogi* – A
814 maize-based complementary food. Food Contr. 86, 224–233.
815 <https://doi.org/10.1016/j.foodcont.2017.11.021>.
- 816 Oplatowska-Stachowiak, M., Reiring, C., Sajic, N., Haasnoot, W., Brabet, C., Campbell, K., et
817 al., 2018. Development and in-house validation of a rapid and simple to use ELISA for

- 818 the detection and measurement of the mycotoxin sterigmatocystin. *Anal. Bioanal. Chem.*
819 410(12), 3017–3023. <https://doi.org/10.1007/s00216-018-0988-8>.
- 820 Ortiz, J., Jacxsens, L., Astudillo, G., Ballesteros, A., Donoso, S., Huybregts, L., et al., 2018.
821 Multiple mycotoxin exposure of infants and young children via breastfeeding and
822 complementary/weaning foods consumption in Ecuadorian highlands. *Food Chem.*
823 *Toxicol.* 118, 541–548. <https://doi.org/10.1016/j.fct.2018.06.008>.
- 824 Oueslati, S., Berrada, H., Mañes, J., Juan, C., 2018. Presence of mycotoxins in Tunisian infant
825 foods samples and subsequent risk assessment. *Food Contr.* 84, 362–369.
826 <https://doi.org/10.1016/j.foodcont.2017.08.021>.
- 827 Oyedele, O.A., Ezekiel, C.N., Sulyok, M., Adetunji, M.C., Warth, B., Atanda, O.O., et al., 2017.
828 Mycotoxin risk assessment for consumers of groundnut in domestic markets in Nigeria.
829 *Int. J. Food Microbiol.* 251, 24–32. <https://doi.org/10.1016/j.ijfoodmicro.2017.03.020>.
- 830 Papageorgiou, M., Wells, L., Williams, C., White, K., De Santis, B., Liu, Y., et al.,
831 2018. Assessment of urinary deoxynivalenol biomarkers in UK children and adolescents.
832 *Toxins.* 10(2), 50. <https://doi.org/10.3390/toxins10020050>.
- 833 Pestka, J.J., 2010. Deoxynivalenol: Mechanisms of action, human exposure, and toxicological
834 relevance. *Arch. Toxicol.* 84, 663–679. <https://doi.org/10.1007/s00204-010-0579-8>.
- 835 Piekkola, S., Turner, P.C., Abdel-Hamid, M., Ezzat, S., El-Daly, M., El-Kafrawy, S., et al., 2012.
836 Characterisation of aflatoxin and deoxynivalenol exposure among pregnant Egyptian
837 women. *Food Addit. Contam. Part A: Chem. Anal. Control Expo. Risk Assess.* 29(6),
838 962–971. <https://doi.org/10.1080/19440049.2012.658442>.
- 839 Polychronaki, N., West, R.M., Turner, P.C., Amra, H., Abdel-Wahhab, M., Mykkänen, H., El-
840 Nezami, H., 2007. A longitudinal assessment of aflatoxin M₁ excretion in breast milk of
841 selected Egyptian mothers. *Food Chem. Toxicol.* 45(7), 1210–1215.
842 <https://doi.org/10.1016/j.fct.2007.01.001>.
- 843 Polychronaki, N., Wild, C.P., Mykkänen, H., Amra, H., Abdel-Wahhab, M., Sylla, A., et al., 2008.
844 Urinary biomarkers of aflatoxin exposure in young children from Egypt and Guinea. *Food*
845 *Chem. Toxicol.* 46(2), 519–526. <https://doi.org/10.1016/j.fct.2007.08.034>.

- 846 Preindl, K., Braun, D., Aichinger, G., Sieri, S., Fang, M., Marko, D., et al., 2019. A generic LC-
847 MS/MS exposome method for the determination of xenoestrogens in biological matrices.
848 *Anal. Chem.* 91(17), 11334–11342. <https://doi.org/10.1021/acs.analchem.9b02446>.
- 849 Rodriguez-Carrasco, Y., Izzo, L., Gaspari, A., Graziani, G., Mañes, J., Ritieni, A., 2018. Urinary
850 levels of enniatin B and its phase I metabolites: first human pilot biomonitoring study.
851 *Food Chem. Toxicol.* 118, 454–459. <https://doi.org/10.1016/j.fct.2018.05.052>.
- 852 Rodriguez-Carrasco, Y., Molto, J.C., Manes, J., Berrada, H., 2014. Exposure assessment
853 approach through mycotoxin/creatinine ration evaluation in urine by GC-MS/MS. *Food*
854 *Chem. Toxicol.* 72, 69–75. <https://doi.org/10.1016/j.fct.2014.07.014>.
- 855 Rubert, J., León, N., Sáez, C., Martins, C.P.B., Godula, M., Yusà, V., et al., 2014. Evaluation of
856 mycotoxins and their metabolites in human breast milk using liquid chromatography
857 coupled to high resolution mass spectrometry. *Anal. Chim. Acta.* 820, 39–46.
858 <https://doi.org/10.1016/j.aca.2014.02.009>.
- 859 Sanchez, E.M., Diaz, G.J., 2019. Frequency and levels of aflatoxin M₁ in urine of children in
860 Bogota, Colombia. *Mycotoxin Res.* 35(3), 271–278. [https://doi.org/10.1007/s12550-019-](https://doi.org/10.1007/s12550-019-00355-x)
861 [00355-x](https://doi.org/10.1007/s12550-019-00355-x).
- 862 SANTE, 2018. Sante/11813/2017 Analytical Quality Control and Method Validation Procedures
863 for Pesticide Residues Analysis.
864 https://ec.europa.eu/food/sites/food/files/plant/docs/pesticides_mrl_guidelines_wrkdoc_2
865 [017-11813.pdf](https://ec.europa.eu/food/sites/food/files/plant/docs/pesticides_mrl_guidelines_wrkdoc_2). Accessed on 8 October 2019.
- 866 Sarkanj, B., Ezekiel, C.N., Turner, P.C., Abia, W.A., Rychlik, M., Krska, R., et al., 2018. Ultra-
867 sensitive, stable isotope assisted quantification of multiple urinary mycotoxin exposure
868 biomarkers. *Anal. Chim. Acta.* 1019, 84–92. <https://doi.org/10.1016/j.aca.2018.02.036>.
- 869 Schwartzbord, J.R., Leroy, J.L., Severe, L., Brown, D.L., 2016. Urinary aflatoxin M₁ in Port-au-
870 Prince and a rural community in north-east Haiti. *Food Addit. Contam. Part A.* 33(6),
871 1036–1042 <https://doi.org/10.1080/19440049.2016.1185899>.
- 872 Shirima, C.P., Kimanya, M.E., Kinabo, J.L., Routledge, M.N., Srey, C., Wild, C.P., et al., 2013.
873 Dietary exposure to aflatoxin and fumonisin among Tanzanian children as determined
874 using biomarkers of exposure. *Mol. Nutr. Food Res.* 57, 1874–1881.
875 <https://doi.org/10.1002/mnfr.201300116>.

- 876 Shirima, C.P., Kimanya, M.E., Routledge, M.N., Srey, C., Kinabo, J.L., Humpf, H.-U., et al.,
877 2015. A prospective study of growth and biomarkers of exposure to aflatoxin and
878 fumonisin during early childhood in Tanzania. *Environ. Health Perspect.* 123(2), 173–
879 178. <https://doi.org/10.1289/ehp.1408097>.
- 880 Silva, L.J.G., Macedo, L., Pereira, A.M.P.T., Duarte, S., Lino, C.M., Pena, A., 2019. Ochratoxin
881 A and Portuguese children: urine biomonitoring, intake estimation and risk assessment.
882 *Food Chem. Toxicol.* 135, 110883. <https://doi.org/10.1016/j.fct.2019.110883>.
- 883 Stadler, D., Sulyok, M., Schuhmacher, R., Berthiller, F., Krska, R., 2018. The contribution of lot-
884 to-lot variation to the measurement uncertainty of an LC-MS-based multi-mycotoxin
885 assay. *Anal. Bioanal. Chem.* 410, 4409–4418. [https://doi.org/10.1007/s00216-018-1096-](https://doi.org/10.1007/s00216-018-1096-5)
886 5.
- 887 Sulyok, M., Stadler, D., Steiner, D., Krska, R., 2020. Validation of an LC-MS/MS-based dilute-
888 and-shoot approach for the quantification of >500 mycotoxins and other secondary
889 metabolites in food crops: challenges and solutions. *Anal. Bioanal. Chem.* 412(11),
890 2607–2620. <https://doi.org/10.1007/s00216-020-02489-9>.
- 891 Sun, G., Wang, S., Hu, X., Su, J., Huang, T., Yu, J., et al., 2007. Fumonisin B₁ contamination of
892 home-grown corn in high-risk areas for esophageal and liver cancer in China. *Food*
893 *Addit. Contam.* 24, 181–185. <https://doi.org/10.1080/02652030601013471>.
- 894 Sun, G., Wang, S., Hu, X., Su, J., Zhang, Y., Xie, Y., et al., 2011. Co-contamination of aflatoxin
895 B₁ and fumonisin B₁ in food and human dietary exposure in three areas of China. *Food*
896 *Addit. Contam. Part A.* 28, 461–470. <https://doi.org/10.1080/19440049.2010.544678>.
- 897 Turconi, G., Guarcello, M., Livieri, C., Comizzoli, S., Maccarini, L., Castellazzi, A.M., et al.,
898 2004. Evaluation of xenobiotics in human milk and ingestion by the newborn. *Eur. J.*
899 *Nutr.* 43(4), 191–197. <https://doi.org/10.1007/s00394-004-0458-2>.
- 900 Turner, P.C., Collinson, A.C., Cheung, Y.B., Gong, Y.Y., Hall, A.J., Prentice, A.M., et al., 2007.
901 Aflatoxin exposure in utero causes growth faltering in Gambian infants. *Int. J. Epidemiol.*
902 36, 1119–1125. <https://doi.org/10.1093/ije/dym122>.
- 903 Turner, P.C., Flannery, B., Isitt, C., Ali, M., Pestka, J., 2012a. The role of biomarkers in
904 evaluating human health concerns from fungal contaminants in food. *Nutr. Res. Rev.* 25,
905 162–179. <http://doi.org/10.1017/S095442241200008X>.

- 906 Turner, P.C., Gong, Y.Y., Pourshams, A., Jafaric, E., Routledge, M.N., Malekzadeh, R., et al.,
907 2012b. A pilot survey for *Fusarium* mycotoxin biomarkers in women from Golestan,
908 northern Iran. *World Mycotoxin J.* 5, 195–199. <https://doi.org/10.3920/WMJ2011.1337>.
- 909 Turner, P.C., Hopton, R., Lecluse, Y., White, K.L.M., Fisher, J., Lebailly, P., 2010. Determinants
910 of urinary deoxynivalenol in male farmers from Normandy, France. *J. Agric. Food Chem.*
911 58, 5206–5212. <https://doi.org/10.1021/jf100892v>.
- 912 Turner, P.C., Moore, S.E., Hall, A.J., Prentice, A.M., Wild, C.P., 2003. Modification of immune
913 function through exposure to dietary aflatoxin in Gambian children. *Environ. Health*
914 *Perspect.* 111, 217–220. <https://doi.org/10.1289/ehp.5753>.
- 915 Turner, P.C., 2013. The molecular epidemiology of chronic aflatoxin driven impaired child
916 growth. *Scientifica.* 2013, 152879. <http://doi.org/10.1155/2013/152879>.
- 917 Vejdovszky, K., Hahn, K., Braun, D., Warth, B., Marko, D., 2017a. Synergistic estrogenic effects
918 of *Fusarium* and *Alternaria* mycotoxins *in vitro*. *Arch. Toxicol.* 91(3), 1447–1460.
919 <https://doi.org/10.1007/s00204-016-1795-7>.
- 920 Vejdovszky, K., Schmidt, V., Warth, B., Marko, D., 2017b. Combinatory estrogenic effects
921 between the isoflavone genistein and the mycotoxins zearalenone and alternariol *in*
922 *vitro*. *Mol. Nutr. Food Res.* 61(3), 1600526. <https://doi.org/10.1002/mnfr.201600526>.
- 923 Vidal, A., Mengelers, M., Yang, S., De Saeger, S., De Boevre, M., 2018. Mycotoxin biomarkers
924 of exposure: a comprehensive review. *Compr. Rev. Food Sci. Food Saf.* 17(5), 1127–
925 1155. <https://doi.org/10.1111/1541-4337.12367>.
- 926 Wang, J.-S., Huang, T., Su, J., Liang, F., Wei, Z., Liang, Y., et al., 2001. Hepatocellular
927 carcinoma and aflatoxin exposure in Zhuqing village Fusui county, People's Republic of
928 China. *Cancer Epidemiol. Biomarkers Prev.* 10, 143–146.
- 929 Warth, B., Braun, D., Ezekiel, C.N., Turner, P.C., Degen, G.H., Marko, D., 2016. Biomonitoring
930 of mycotoxins in human breast milk: current state and future perspectives. *Chem. Res.*
931 *Toxicol.* 29(7), 1087–1097. <https://doi.org/10.1021/acs.chemrestox.6b00125>.
- 932 Warth, B., Preindl, K., Manser, P., Wick, P., Marko, D., Buerki-Thurnherr, T., 2019. Transfer and
933 metabolism of the xenoestrogen zearalenone in human perfused placenta. *Environ.*
934 *Health Perspect.* 127(10), 107004. <https://doi.org/10.1289/EHP4860>.

- 935 Warth, B., Sulyok, M., Krska, R., 2013. LC-MS/MS-based multibiomarker approaches for the
936 assessment of human exposure to mycotoxins. *Anal. Bioanal. Chem.* 405(17), 5687–
937 5695. <https://doi.org/10.1007/s00216-013-7011-1>.
- 938 Watson, S., Moore, S., Darboe, M.K., Chen, G., Tu, Y.-K., Huang, Y.-T., et al., 2018. Impaired
939 growth in rural Gambian infants exposed to aflatoxin: a prospective cohort study. *BMC.*
940 *Public Health.* 18, 1247. <https://doi.org/10.1186/s12889-018-6164-4>.
- 941 Wild, C.P., Turner, P.C., 2002. The toxicology of aflatoxins as a basis for public health
942 decisions. *Mutagenesis.* 17, 471–481. <https://doi.org/10.1093/mutage/17.6.471>.
- 943 Woelflingseder, L., Warth, B., Vierheilig, I., Schwartz-Zimmermann, H., Hametner, C., Nagl, V.,
944 et al., 2019. The *Fusarium* metabolite culmorin suppresses the *in vitro* glucuronidation of
945 deoxynivalenol. *Arch. Toxicol.* 93(6), 1729–1743. [https://doi.org/10.1007/s00204-019-](https://doi.org/10.1007/s00204-019-02459-w)
946 02459-w.
- 947 Wu, X., Jackson, R.T., Khan, S.A., Ahuja, J., Pehrsson, P.R., 2018. Human milk nutrient
948 composition in the United States: current knowledge, challenges, and research needs.
949 *Curr. Develop. Nutr.* 2(7), nzy025. <https://doi.org/10.1093/cdn/nzy025>.
- 950 Yoshizawa, T., Yamashita, A., Luo, Y., 1994. Fumonisin occurrence in corn from high- and low-
951 risk areas for human esophageal cancer in China. *Appl. Environ. Microbiol.* 60, 1626–
952 1629.

953 **Table captions:**

954 **Table 1.** Demographic characteristics and food preference of study participants.

955 **Table 2.** Mycotoxins in breast milk ($n=22$) consumed by exclusively breastfed infants in Ogun
956 state, Nigeria.

957 **Table 3.** Mycotoxins in plate-ready complementary food fed to non-exclusively breastfed infants
958 in Ogun state, Nigeria.

959 **Table 4.** Mycotoxins in urines of exclusively breastfed (EB) and non-exclusively breastfed (NEB)
960 infants in Ogun state, Nigeria.

961 **Table 5.** Co-occurrence of mycotoxin classes^a in breast milk, complementary food and urine.

962

963 **Table S1.** Fungal metabolites in plate-ready complementary food fed to non-exclusively
964 breastfed infants in Ogun state, Nigeria.

965 **Figure captions:**

966 **Figure 1.** MRM-chromatograms of a matrix-matched standard in urine (A), and an infant urine
967 sample (B) of aflatoxin Q₁ (AFQ₁) and dihydrocitrinone (DHC), respectively. In addition,
968 MRM-chromatograms of a matrix-matched standard in breast milk (C) and a breast milk
969 sample (D) of DHC and sterigmatocystin (STER), respectively, are shown. Quantifier,
970 qualifier and retention time are given for each mycotoxin: AFQ₁ (*m/z* 329.0–282.9; *m/z*
971 329.0–175.0; RT: 15.1 min) and DHC (*m/z* 265.0–221.1; *m/z* 265.0–246.9; RT: 16.1 min)
972 in urine; DHC (*m/z* 265.0–177.0; *m/z* 265.0–203.0; RT: 4.5 min) and STER (*m/z* 325.1–
973 281.1; *m/z* 325.1–310.2; RT: 8.1 min) in breast milk.

974 **Figure 2.** Scatter plot for percentage increases in detection frequencies and means of detects
975 of mycotoxins in urine of non-exclusively breastfed (NEB) vs. exclusively breastfed (EB)
976 infants in Ogun state, Nigeria. Numerals on x-axis denote mycotoxins: 1 = aflatoxin M₁; 2
977 = aflatoxin Q₁; 3 = deoxynivalenol; 4 = dihydrocitrinone; 5 = fumonisin B₁; 6 = ochratoxin
978 A; 7 = zearalenone; 8 = β-zearalenol.

979 **Figure 3.** MRM-chromatogram of one non-exclusively breastfed infant urine sample from Ogun
980 state, Nigeria, containing a mixture of seven mycotoxins belonging to six mycotoxin
981 classes. Quantifier, qualifier, internal standard (IS) and retention time are given for each
982 mycotoxin: DON (*m/z* 355.1–246.9; *m/z* 355.1–137.9; *m/z* 370.1–278.8; RT: 9.0 min),
983 AFQ₁ (*m/z* 329.0–282.9; *m/z* 329.0–175.0; no IS; RT: 15.0 min), AFM₁ (*m/z* 329.1–
984 273.2; *m/z* 329.1–229.1; *m/z* 346.0–288.2; RT: 15.1 min), FB₁ (*m/z* 722.5–334.4; *m/z*
985 722.5–352.3; *m/z* 756.3–356.3; RT: 15.1 min), DHC (*m/z* 265.0–221.1; *m/z* 265.0–246.9;
986 no IS; RT: 15.9 min), OTA (*m/z* 404.0–239.0; *m/z* 404.0–358.0; *m/z* 424.2–250.1; RT:
987 20.6 min), and ZEN (*m/z* 317.1–175.0; *m/z* 317.1–131.0; *m/z* 335.2–185.1; RT: 20.8
988 min).

989 **Table 1.** Demographic characteristics and food preference of study participants.

Characteristics	All	Exclusively breastfed	Non-exclusively breastfed
Subjects (<i>n</i> (%))	65	23 (35.4)	42 (64.6)
Gender (<i>n</i> (%))			
Male	31 (47.7)	11 (47.8)	20 (47.6)
Female	34 (52.3)	12 (52.2)	22 (52.4)
Age (months)			
Mean \pm SD ^a	7.1 \pm 3.9	3.7 \pm 1.6	9.0 \pm 3.6*
Range	1–18	1–6	3–18
Body weight (kg)			
Mean \pm SD ^a	7.4 \pm 1.7	6.3 \pm 1.0	8.0 \pm 1.6**
Range	4.5–11.2	4.5–8.0	5.0–11.2
Frequency of food consumption/day			
Breast milk	1–>10	8–>10 ^b	1–3
Complementary food	3–5	0	3–5
Complementary food (<i>n</i> (%)) preference			
Single food (e.g. <i>ogi</i>)	3 (4.6)	0 (0)	3 (7.1)
Mixed foods ^c	39 (60.0)	0 (0)	39 (92.9)

990 ^aStandard deviation.

991 ^bAs reported by Braun et al. (2018).

992 ^cCombination of complementary foods (e.g. infant cereal, *ogi* and *Tombran*) consumed in a day.

993 *Significant at $p < 0.01$, ** $p < 0.05$

994 **Table 2.** Mycotoxins in breast milk ($n = 22$) consumed by exclusively breastfed infants in Ogun
 995 state, Nigeria.

Mycotoxins	LOD (ng/L)	LOQ (ng/L)	N (%) ^a	Concentration (ng/L)		
				Range	Median	Mean
Aflatoxin M ₁	2.0	4.0	4 (18.2)	2.0 ^b	2.0	2.0
Alternariol monomethyl ether	0.5	1.0	21 (95.5)	0.5 ^b –11.7	1.8	3.0
Beauvericin	0.1	0.3	22 (100)	1.0–12.0	2.2	3.0
Dihydrocitrinone	14.0	28.0	6 (27.3)	14.0 ^b –59.7	14.0	25.2
Enniatin B	0.7	1.4	16 (72.7)	0.7 ^b –10.1	4.6	5.0
Enniatin B ₁	0.5	1.0	5 (22.7)	0.5 ^b –1.15	0.5	0.6
Ochratoxin A	2.0	4.0	14 (63.6)	2.0 ^b –67.6	2.0	9.6
Ochratoxin B	2.5	5.0	2 (9.1)	5.3–6.7	6.0	6.0
Sterigmatocystin	0.5	1.0	1 (4.6)	1.2	1.2	1.2

996 ^aNumber (and percentage) of samples containing the mycotoxin.

997 ^b<LOQ values were considered as positive data and substituted with LOQ/2.

998 **Table 3.** Mycotoxins in plate-ready complementary food fed to non-exclusively breastfed infants in Ogun state, Nigeria.

Mycotoxins	LOD (µg/kg)	LOQ (µg/kg)	All samples (n=42)			Infant cereal (n=6)		Ogi (n=26)		Tombran (n=10)	
			N (%) ^a	Range ^b	Mean ^b ±SD	N	Mean ^b	N	Mean ^b	N	Mean ^b
Aflatoxin B ₁	0.24	0.72	9 (21.4)	1.0–7.0	3.0 ± 2.0	0	<LOD	6	2.5	3	4.1
Aflatoxin B ₂	0.4	1.2	1 (2.4)	1.2	1.2	0	<LOD	0	<LOD	1	1.2
Aflatoxin G ₁	0.32	0.96	2 (4.8)	12.0–12.1	12.1 ± 0.0	0	<LOD	2	12.1	0	<LOD
Total aflatoxin^c	-	-	9 (21.4)	1.0–16.2	5.8 ± 6.3	0	<LOD	6	6.5	3	4.5
Beauvericin	0.008	0.024	33 (78.6)	0.1–116	3.8 ± 20.1	6	19.4	19	0.3	8	0.3
Deoxynivalenol	1.2	3.6	2 (4.8)	52.9–61.5	57.2 ± 6.1	1	52.9	1	61.5	0	<LOD
Enniatin A ₁	0.032	0.096	7 (16.7)	0.1–5.7	1.3 ± 2.0	2	3.3	1	0.9	4	0.4
Enniatin B	0.024	0.072	8 (19.0)	0.03–6.9	2.1 ± 3.0	2	6.9	1	1.1	5	0.4
Enniatin B ₁	0.04	0.12	6 (14.3)	0.4–14.3	4.1 ± 5.3	2	9.6	1	2.2	3	1.1
Enniatin B ₂	0.04	0.12	3 (7.1)	0.09–0.34	0.22 ± 0.13	2	0.29	0	<LOD	1	0.09
Fumonisin A ₁	2	6.0	1 (2.4)	2.0	2.0	0	<LOD	1	2.0	0	<LOD
Fumonisin B ₁	3.2	9.6	11 (26.2)	13.8–114	35.6 ± 32.2	2	54.2	7	35.3	2	18.0
Fumonisin B ₂	2.4	7.2	8 (19.0)	7.9–80.3	24.3 ± 24.0	1	17.8	6	26.7	1	15.8
Total fumonisin^d	-	-	12 (28.6)	7.9–194	48.8 ± 52.9	2	63.1	8	50.9	2	25.9
Moniliformin	1.6	4.8	3 (7.1)	7.2–10.6	8.6 ± 1.8	0	<LOD	0	<LOD	3	8.6
Zearalenone	0.12	0.36	4 (9.5)	0.5–6.8	2.4 ± 3.0	1	0.6	2	1.1	1	6.8

999 ^aNumber (and percentage) of samples containing the mycotoxin. ^bMean (and standard deviation) of mycotoxin concentrations expressed in µg/kg.

1000 ^cSum of aflatoxins B₁, B₂ and G₁.

1001 ^dSum of fumonisins B₁ and B₂.

1002 **Table 4.** Mycotoxins in urines of exclusively breastfed (EB) and non-exclusively breastfed (NEB) infants in Ogun state, Nigeria.

Mycotoxins	LOD (ng/L)	LOQ (ng/L)	Quantified levels (ng/L)					
			Exclusively breastfed (<i>n</i> =23)			Non-exclusively breastfed (<i>n</i> =42)		
			<i>N</i> (%) ^a	Range	Mean ^b	<i>N</i> (%) ^a	Range	Mean ^b
Aflatoxin M ₁	0.3	1.0	1 (4)	23	23	5 (12)	32–505	166
Aflatoxin Q ₁	0.3	1.0	20 (87)	3–791	182	24 (57)	14–898	225*
Deoxynivalenol	50	150	7 (30)	225–19,781	3194	23 (55)	226–21,344	5282*
Dihydrocitrinone	3.0	10	6 (26)	5–944	135	31 (74)	5–1,377	202*
Fumonisin B ₁	1.0	10	4 (17)	35–188	136	13 (31)	47–1,587	454*
Nivalenol	50	100	<i>nd</i>	<i>nd</i>	<i>nd</i>	1 (2)	161	161
Ochratoxin A	0.3	1.0	6 (26)	0.5–76	19*	16 (38)	0.5–34	9
Zearalenone	1.0	3.0	13 (57)	17–784	148	35 (83)	13–678	140
α-Zearalenol	3.0	10	<i>nd</i>	<i>nd</i>	<i>nd</i>	7 (17)	5–55	20
β-Zearalenol	1.0	3.0	7 (30)	8–648	122	6 (14)	14–68	32

1003 ^aNumber (percentage) of children with quantifiable mycotoxin levels in urine.

1004 ^bMean values were calculated to include <LOQ data points substituted with half LOQ.

1005 *Significant at *p*<0.05.

1006

1007 **Table 5.** Co-occurrence of mycotoxin classes^a in breast milk, complementary food and urine.

Numbers of mycotoxins	Incidence [<i>N</i> (%)] ^b in infant's food		Incidence [<i>N</i> (%)] ^b in infant's urine		
	Complementary		Exclusively breastfed (<i>n</i> =23)	Non-exclusively breastfed (<i>n</i> =42)	All (<i>n</i> =65)
	Breast milk (<i>n</i> =22)	food (<i>n</i> =42)			
0	0 (0)	0 (0)	1 (4.3)	0 (0)	1 (1.5)
1	0 (0)	20 (47.6)	5 (21.7)	3 (7)	8 (12.3)
2	3 (13.6)	13 (31.0)	5 (21.7)	5 (11.9)	10 (15.4)
3	5 (22.8)	4 (9.5)	3 (13.0)	12 (28.6)	15 (23.1)
4	9 (40.9)	4 (9.5)	7 (30.4)	12 (28.6)	19 (29.2)
5	2 (9.1)	1 (2.4)	2 (8.7)	9 (21.4)	11 (16.9)
6	3 (13.6)	0 (0.0)	0 (0.0)	1 (2.4)	1 (1.5)

1008 ^aMycotoxin classes: aflatoxins (breast milk: AFM₁; food: AFB₁, AFB₂ and AFG₁; urine: AFM₁ and AFQ₁); alternariolmethylether; beauvericin; dihydrocitrinone;
 1009 deoxynivalenol; dihydrocitrinone (breast milk and urine); enniatins (breastmilk: ENNB and ENNB₁; food: ENNA₁, ENNB, ENNB₁ and ENNB₂); fumonisins (food: FB₁
 1010 and FB₂; urine: FB₁); moniliformin; nivalenol; ochratoxins (breast milk: OTA and OTB; urine: OTA); sterigmatocystin (breast milk); zearalenone (food: zearalenone;
 1011 urine: zearalenone, α-zearalenol and β-zearalenol).

1012 ^bNumber (and percentage) of samples containing co-occurring mycotoxin classes. <LOQ values were considered as positive data.


1013 **Table S1.** Fungal metabolites in plate-ready complementary food fed to non-exclusively breastfed infants in Ogun state, Nigeria.

Metabolites	LOD (µg/kg)	All samples (n=42)			Infant cereal (n=6)		Ogi (n=26)		Tombran (n=10)	
		N (%) ^a	Range ^b	Mean ^b ±SD	N	Mean ^b	N	Mean ^b	N	Mean ^b
3-Nitropropionic acid	0.8	2 (4.76)	11.7-20.6	16.2±6.30	0	<LOD	2	16.2	0	<LOD
Agroclavine	0.12	4 (9.52)	12.6-532	243±216	0	<LOD	1	12.6	3	320
Asperglaucide	0.08	31 (73.8)	0.08-90.3	9.87±22.1	6	2.15	16	0.90	9	31.0
Asperphenamate	0.04	24 (57.1)	0.06-32.2	4.11±8.90	2	3.45	14	0.42	8	10.7
Averantin	0.04	2 (4.76)	0.38-0.88	0.63±0.35	0	<LOD	2	0.63	0	<LOD
Averufin	0.04	7 (16.7)	0.04-2.54	0.88±1.10	1	0.04	4	1.34	2	0.38
Brevianamid F	0.16	12 (28.6)	0.35-24.1	9.06±8.10	2	9.39	5	3.18	5	14.8
cyclo(L-Pro-L-Tyr)	0.8	26 (61.9)	0.81-25.9	7.00±8.13	7	5.07	11	2.57	8	14.8
cyclo(L-Pro-L-Val)	0.64	39 (92.9)	0.65-71.0	16.8±18.7	7	22.6	22	8.35	10	31.2
Elymoclavine	0.4	7 (16.7)	0.99-45.9	16.6±16.9	0	<LOD	2	1.10	5	22.8
Emodin	0.056	2 (4.76)	0.98-1.01	1.00±0.02	0	<LOD	2	1.00	0	<LOD
Fellutanine A	0.2	4 (9.52)	6.00-10.0	8.22±1.99	0	<LOD	2	7.89	2	8.55
Festuclavine	0.08	3 (7.14)	2.65-4.74	3.53±1.08	0	<LOD	0	<LOD	3	3.53
Flavoglaucin	0.24	7 (16.7)	0.54-57.5	17.0±24.4	1	0.67	2	52.3	4	3.43
Kojic acid	16	9 (21.4)	17.0-956	142±306	0	<LOD	4	260	5	46.7
Macrosporin	0.04	3 (7.14)	0.07-1.10	0.42±0.59	0	<LOD	0	<LOD	3	0.42
N-Benzoyl-Phenylalanine	0.064	22 (52.4)	0.33-11.9	2.03±3.13	2	0.92	12	0.90	8	4.00
Neoechinulin A	0.8	3 (7.14)	4.33-17.4	11.7±6.71	0	<LOD	2	15.5	1	4.33
O-MethylSterigmatocystin	0.12	2 (4.76)	0.35-0.41	0.38±0.04	0	<LOD	2	0.38	0	<LOD
Questiomycin A	2	1 (2.38)	5.58	5.58	0	<LOD	1	5.58	0	<LOD
Quinolactacin A	0.08	5 (11.9)	0.10-0.66	0.35±0.25	1	0.23	3	0.48	1	0.10
Rugulusovin	0.64	9 (21.4)	0.71-8.33	3.72±2.79	1	3.85	5	4.48	3	2.41
Skyrin	0.4	1 (2.38)	0.91	0.91	0	<LOD	1	0.91	0	<LOD
Tryptophol	8	27 (64.3)	8.88-792	87.2±180	4	49.0	14	88.7	9	102
Versicolorin C	0.24	2 (4.76)	0.58-0.62	0.60±0.02	0	<LOD	2	0.60	0	<LOD


^aNumber (percentage) of samples containing the metabolite.

^aConcentrations expressed in µg/kg.

1014
1015



1016
1017 **Figure 1.** MRM-chromatograms of a matrix-matched standard in urine (A), and an infant urine
1018 sample (B) of aflatoxin Q₁ (AFQ₁) and dihydrocitronone (DHC), respectively. In addition, MRM-
1019 chromatograms of a matrix-matched standard in breast milk (C) and a breast milk sample (D) of
1020 DHC and sterigmatocystin (STER), respectively, are shown. Quantifier, qualifier and retention
1021 time are given for each mycotoxin: AFQ₁ (*m/z* 329.0–282.9; *m/z* 329.0–175.0; RT: 15.1 min) and
1022 DHC (*m/z* 265.0–221.1; *m/z* 265.0–246.9; RT: 16.1 min) in urine; DHC (*m/z* 265.0–177.0; *m/z*
1023 265.0–203.0; RT: 4.5 min) and STER (*m/z* 325.1–281.1; *m/z* 325.1–310.2; RT: 8.1 min) in
1024 breast milk.



1025


1026 **Figure 2.** Scatter plot for percentage increases in detection frequencies and means of detects

1027 of mycotoxins in urine of non-exclusively breastfed (NEB) vs. exclusively breastfed (EB) infants

1028 in Ogun state, Nigeria. Numerals on x-axis denote mycotoxins: 1 = aflatoxin M₁; 2 = aflatoxin Q₁;

1029 3 = deoxynivalenol; 4 = dihydrocitrinone; 5 = fumonisin B₁; 6 = ochratoxin A; 7 = zearalenone; 8

1030 = β -zearalenol.



1031

1032 **Figure 3.** MRM-chromatogram of one non-exclusively breastfed infant urine sample from Ogun

1033 state, Nigeria, containing a mixture of seven mycotoxins belonging to six mycotoxin classes.

1034 Quantifier, qualifier, internal standard (IS) and retention time are given for each mycotoxin: DON

1035 (*m/z* 355.1–246.9; *m/z* 355.1–137.9; *m/z* 370.1–278.8; RT: 9.0 min), AFQ₁ (*m/z* 329.0–282.9;

1036 *m/z* 329.0–175.0; no IS; RT: 15.0 min), AFM₁ (*m/z* 329.1–273.2; *m/z* 329.1–229.1; *m/z* 346.0–

1037 288.2; RT: 15.1 min), FB₁ (*m/z* 722.5–334.4; *m/z* 722.5–352.3; *m/z* 756.3–356.3; RT: 15.1 min),

1038 DHC (*m/z* 265.0–221.1; *m/z* 265.0–246.9; no IS; RT: 15.9 min), OTA (*m/z* 404.0–239.0; *m/z*

1039 404.0–358.0; *m/z* 424.2–250.1; RT: 20.6 min), and ZEN (*m/z* 317.1–175.0; *m/z* 317.1–131.0;

1040 *m/z* 335.2–185.1; RT: 20.8 min).